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Resistance to every class of antibiotics has been identified clinically. The rapid development and
spread of resistance is responsible for the diminished lifetime of many once efficacious
therapeutics. Trimethoprim (TMP), a clinically important dihydrofolate reductase (DHFR)
inhibitor, remains a first line treatment for Staphylococcus aureus infections but its continued
use is threatened by the emergence of resistance. Identifying and understanding the
mechanisms of trimethoprim resistance is crucial for the development for novel antibiotics to
overcome the contemporary clinical resistances. Trimethoprim resistance is conferred through
both the acquisition of mutations in the endogenous DHFR enzyme and of innately resistant
enzymes. Guided by structure based drug design, a novel class of DHFR inhibitors, known as
propargyl-linked antifolates (PLAs), has been developed to directly overcome trimethoprim
resistance in Staphylococcus aureus. By doing this, we identified the contemporary
mechanisms of antifolate resistance, developed a molecular understanding of reported and
prospective mutational resistance mechanisms and generated a class of potent inhibitors
against both wild type and TMPR DHFR enzymes and S. aureus strains. In addition to their
potent activity, these inhibitors also reveal unique binding and plasticity of both the inhibitor and
co-factor binding sites, leading to the discovery of a novel NADPH configuration. In all, these
efforts led to a comprehensive understanding of antifolate S. aureus and the development of
potent inhibitors that overcome these resistance mechanisms.
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Chapter 1
The Clinical Burden of Staphylococcus aureus

Prior the introduction of penicillin in the 1940’s, infections from minor cuts and scrapes
could lead to blood poisoning and death. In fact, mortality rates of greater than 85% for
blood infections during that time have been reported1. Penicillin, a beta-lactam antibiotic,
was discovered by Alexander Fleming in London in the late 1920’s and introduced to the
clinic in the 1940’s. Its discovery is regarded as one of the most significant advances in
medicine. As the first accessible antibiotic, penicillin reduced the amount of infection
related deaths and played a historic role in World War II, where the number of wounded
soldier fatalities decreased significantly1. After its mass production and wide spread use,
penicillin resistant bacteria began presenting a significant clinical burden in the mid
1940’s and its spread to communal settings in the 1950’s sparked the development of
new antibiotics. The clinical introduction of methicillin in the 1960’s reduced the burden of
penicillin resistant bacteria, but like penicillin, resistance to methicillin developed rapidly2.
The first methicillin-resistant S. aureus (MRSA) isolate was reported in England in 19613
and later appearing in the US in 19684. Unlike penicillin, the development of methicillin
resistance conferred broad resistance to the entire class of beta-lactam antibiotics2.

Every year, approximately 700,000 people worldwide die of drug resistant infections5.
According to the Antibiotic Threat Report released by the Centers for Disease Control
released in 2013, more than 2 million Americans contract a drug resistant infection and at
least 23,000 people die directly of the disease6. The urgent nature of drug resistance has
prompted Presidential Priority in the 2016 Science and Technology Fiscal Budget in
which it was declared that funding should be prioritized to the development of new
1

antibiotic resistance countermeasures including vaccines, small molecule inhibitors,
synergists as well as implementing increased stewardship and surveillance measures7.
The continued rise of antibiotic resistance and multi-drug resistant bacteria, a result of
clinical and agricultural antibiotic misuse, is diminishing the efficacy of once powerful
antibiotics. Therefore, the need to develop new, robust antibiotics is met with the need to
understand the current state of clinical resistance and a strategy to overcome these
resistances.

1.1

The Impact of Staphylococcus aureus

Methicillin resistant Staphylococcus aureus (MRSA), an opportunistic gram-positive
bacterium, is the leading cause of invasive systemic infections, pneumonia as well as skin
and soft tissue infections (SSTIs) worldwide. MRSA is the most common cause of
healthcare-associated infections occurring during or shortly after inpatient care8. The
Centers for Disease Control (CDC) reports over 80,000 invasive MRSA infections
annually in the United States, more than 11,000 of these infections are fatal. The
widespread and often critical nature of these infections prompted the CDC to classify drug
resistant MRSA as a ‘Serious Threat’, as it poses a significant risk to public health6. As of
2005, S. aureus accounted for 18.7% of inpatient bacterial specimens and 14.7% of
outpatient bacterial specimens. Of those strains, 55% of ICU isolates, 59% of general
hospital and 48% of outpatient infections were resistant to methicillin9.

MRSA infections can be healthcare (HA-MRSA) or community (CA-MRSA) associated;
CA-MRSA and HA-MRSA are genetically distinct. Community associated MRSA can
infect healthy populations that have no defined risk factors, specifically children and
young adults. About 90% of CA-MRSA infections are uncomplicated skin and soft tissue
2

infections (SSTIs) such as cellulitis, however due to increased virulence often affiliated
with these strains, they are able to advance in severity to necrotizing fasciitis, necrotizing
pneumonia and even death2,10. The ability of CA-MRSA to cause severe infections is
highly correlated with the presence of Panton-Valentine leukocidin (PVL) genes. PantonValentine leukocidin is a cytotoxin that causes leukocyte destruction, allowing for its
evasion

from

immune

system

and

allowing

for

infection

advancement.11,12

Healthcare or hospital associated MRSA infections are considered those that occur in
response to hospitalization and are often associated with biofilm formation14. Patients
who have undergone surgery, dialysis, require a catheter or reside in a long-term medical
care facility are said to be predisposed to HA-MRSA; if a patient does not possess one of
these risk factors, they are considered to have a CA-MRSA infection13. However, since
CA-MRSA has become an epidemic within health care systems, the epidemiological
distinction between CA-and HA-MRSA isolates becomes complicated8, 11. HA- and CAMRSA genotypes can be determined by identifying the staphylococcal chromosomal
cassette mec (SCCmec), a genetic feature common to all MRSA isolates and unique to
the epidemiological lineage of the strains12.

The antibiotic combination, trimethoprim and sulfamethoxazole, is the first line therapy for
uncomplicated MRSA infections. However, these uncomplicated MRSA infections can
also be successfully treated with non-penicillin antibiotics including tetracyclines,
macrolides, fluoroquinolones, aminoglycosides and linezolid. Complicated SSTIs and
systemic infections that require hospitalization are treated with intravenous vancomycin or
daptomycin, both glycopeptide antibiotics; with the most severe and complicated
infections requiring combination therapies15. In addition to having a major clinical
3

presence, the ability of MRSA to rapidly develop antibiotic resistance is especially
concerning as it has significantly limited the available treatment options; clinical
resistance to all aforementioned antibiotics has been reported in S. aureus.

1.2 The Folic Acid Cycle and Antifolates
1.2a The Folic Acid Cycle
Both trimethoprim and sulfamethoxazole belong to a class of antibiotics called antifolates
as they inhibit enzymes within the folic acid cycle. Folate metabolism, via the folic acid
cycle, is essential for the production of deoxythymidine monophosphate (dTMP), purine
nucleotides, methionine and histidine; all of which are required for successful DNA
replication and protein synthesis (Figure 1). During the cycle, p-amino benzoic acid and
dihydropteroate pyrophosphate are consumed by dihydropteroate synthase for the
generation of dihydropteroate. Dihydropteroate is then used for the synthesis of
dihydrofolate (DHF) by reaction with dihydrofolate synthase. DHF is then reduced to
tetrahydrofolate (THF) via the oxidation of NADPH by dihydrofolate reductase followed by
a cyclization to N5,N10-methylene THF by a serine hydroxymethyl transferase. DHF is
regenerated by the thymidylate synthase from N5,N10-methylene THF resulting in the
methylation of dUMP to dTMP, a nucleotide used in DNA synthesis. Additionally, N5,N10methylene THF is further reduced downstream of serine hydroxymethyl transferase by
N5,N10-methyleneTHF reductase for methionine generation and N5,N10-methylenyl THF
reductase for both histidine and purine nucleotide synthesis (Figure 1)16. Unlike bacteria
where DHF is synthesized de novo, eukaryotic cells rely on dietary intake as their source
of folate and actively transport folic acid across the plasma membrane via Reduced
Folate Transporters (RFT). Once in the cell, DHFR reduces folic acid to dihydrofolate,

4

which then undergoes a second enzymatic reduction by DHFR to THF prior to completion
of the cycle17.

Figure 2 Bacterial folic acid cycle; enzymes are in bold and end products (dTMP, amino
acids and nucleotides) are boxed16.

5

1.2b Dihydrofolate Reductase
Dihydrofolate Reductase is an essential enzyme within the folic acid cycle responsible for
the reduction of dihydrofolate to tetrahydrofolate via the oxidation of NADPH to
NADP+(Figure 2a). S. aureus DHFR, is 158 amino acids with a molecular weight of 17.4
kDa. The ternary protein structure features an 8- strand beta sheet surrounded by four
alpha helices all connected through flexible loop regions. The substrate (DHF) forms
several ionic interactions between the pterin moiety and the side chain of Asp 27 and
backbone carbonyl of Phe 92 as well as a hydrophobic interaction with the side chain of
Leu 28 and the amino benzoate ring (Figure 2b). The pterin amine group forms a
hydrogen bond with a water molecule involved in an extensive water network coordinated
throughout the protein as well extensive van der Waals interactions with the nicotinamide
ring. Additionally, two crucial hydrogen-bonding interactions are formed between the
glutamate tail and guanidinium moiety of the Arg 57 (Figure 2b)18.

6

Figure 2 a) The mechanism of DHFR b) Folate and NADPH (purple) bound in the S.
aureus DHFR (blue) active site. The amino acids and interactions made with DHF are
highlighted (PDB ID: 3FRD).

During its catalytic cycle, DHF and NADPH form a ternary structure with DHFR. Upon
reduction of DHF to THF through the oxidation of NADPH, NADP+ is released from the
active site leaving a binary complex of DHFR and THF. NADPH then binds the binary
complex, releasing THF and allowing a new DHF molecule to bind, perpetuating
catalysis19. After its release from the enzyme, THF is transformed into methylene-THF
and continues through the folic acid cycle until it is regenerated by thymidylate synthase.

7

DHFR is the only source of THF for bacterial cells, therefore its inhibition results in
arrested cell proliferation. As such, DHFR is a considered an essential enzyme and
validated drug target exploited for the treatment of cancer, autoimmune disease as well
as bacterial and parasitic infections.

1.2c Clinical Antifolates
Antifolates are inhibitors of folic acid enzymes including dihydrofolate reductase,
thymidylate synthase (TS) and dihydropteroate synthase (DHPS). This class is clinically
important for the treatment of cancers, infectious diseases and autoimmune disorders.
Trimethoprim (TMP) is the only DHFR inhibitor approved for the treatment of bacterial
infections (Figure 3). TMP is often prescribed in combination with sulfamethoxazole
(SMX)

and

branded

as

Bactrim.

Sulfamethoxazole

is

an

antifolate

targeting

dihydropteroate synthase, an enzyme upstream from DHFR in the folic acid cycle. Both
trimethoprim and sulfamethoxazole are bacteriostatic antibiotics, but together act
synergistically resulting in a potent, bactericidal combination16. TMP has activity against
gram-negative and gram-positive bacteria and TMP/SMX combination is first line
treatment for CA-MRSA infections20-23. Trimethoprim is highly selective for susceptible,
pathogenic DHFR over the human isoform (>8,600-fold) resulting in low-toxicity. In
addition to its general tolerability, the combination is both orally bioavailable and available
at minimal costs, increasing its clinical appeal23. In fact, prescriptions of TMP-SMX
numbered more than 21 million in 2013, putting it in the group of top ten oral antibiotics
prescribed in 201324.

Unlike beta-lactam antibiotics, whose drug class is made up of many generations of
inhibitors, no major effort to generate second-generation antifolate antibiotics has been
8

successful. Iclaprim, a TMP derivative, showed potent activity against gram-positive
bacteria including staphylococci and streptococci and went through clinical trials for
complicated SSTIs and hospital acquired pneumonia infections25-27. However in 2009,
Iclaprim was denied FDA approval upon completion of Phase III trials due a lack of
efficacy and safety, as it possessed a potent inhibitory activity of hERG channel28.
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Figure 3 Structures of Clinically Approved and Relevant DHFR Inhibitors

In addition to its role as anti-bacterial therapeutics, DHFR has been exploited as the
target for anti-cancer drugs, methotrexate (MTX) and pemetrexed, referred to as Classical
Antifolates. Methotrexate is marketed for treatment of cancer, alone and in combination
therapies, as well as for autoimmune disorders including rheumatoid arthritis, psoriasis
and lupus. However, MTX is believed to work through different mechanisms of action for
these non-cancer indications29. Pemetrexed is most recently approved DHFR inhibitor
and is indicated for the treatment of non-small cell lung cancer and pleural mesothelioma
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in combination with cisplatin30. In addition to DHFR inhibitition, pemetrexed also targets
thymidylate synthase and GARFT, a ribonucleotide formyltransferase (Figure 3).

Like dihydrofolate, these classical antifolates possess a basic head group and a
negatively charged glutamate extension that are critical for binding of the enzyme.
Because of the structural similarities, these compounds mimic the binding motif of the
substrate with a basic nitrogenous headgroup that forms strong contacts with an acidic
residue in the active site and a glutamate tail that forms extensive ionic interactions with a
basic amino acid31-33. As substrate mimics, classical antifolates often possess very high
affinity for DHFR enzymes, with low nano-molar to pico-molar potency towards human
and pathogenic enzymes including E. coli and S. aureus34,35. Like folate, classical
antifolates are actively transported into eukaryotic cells though folate transporters. As
bacteria synthesize folate through a de novo mechanism and do not possess folate
transport capabilities, there is no mechanism by which these classical antifolates can
penetrate bacterial cells and therefore show poor efficacy against these species
regardless of the high enzyme affinity29.

1.3 Antibiotic Resistance in S. aureus
Resistance to every class of antibiotics has been identified clinically. Drug resistance is
responsible for increased morbidity, mortality and healthcare costs, estimates range from
$20-35 billion in the US alone6. There are several major resistance mechanisms that
affect antibiotics namely efflux of the drug from the cell, enzymatic modification of the
drug, target mutations that reduce affinity of the drug, up-regulation of the target and
permeability changes to the membrane. Methods in which a resistance-conferring
enzyme is acquired by the cell, specifically an innately resistant target or a drug/ target
10

modifying enzyme, are often transferred between species on plasmid, mobile genetic
elements, and incorporated into the chromosome via horizontal gene transfer. However,
over-expression of the drug target or efflux pumps as well as changes in the drug target
reducing drug affinity are a result of the accumulation of genetic mutations either in the
gene’s promoter region or within the gene itself36.

1.3a Mutational Resistance
Point mutations in the target enzyme result in reduced affinity between the target and
inhibitor by directly or allosterically hindering inhibitor binding. Fluoroquinolones, including
ciprofloxacin and levofloxacin, target DNA gyrase (gyrA) and DNA topoisomerase IV (grlA
and grlB), enzymes essential for DNA replication. The primary mechanism of resistance
to fluroquinolones is a stepwise accumulation of mutations in these genes many of which
are in the “quinolone resistance determining region” (QRDR) in the gyrA subunit37.
Additionally, sulfamethoxazole resistance is conferred by the accumulation of up to 13
mutations in folP, the gene for DHPS, resulting in high level resistance38. Importantly, the
formation of the mutations, as with other resistance mechanisms, must confer resistance
without sacrificing the endogenous function of the enzyme, as enzymes or cells with
reduced fitness are less likely to survive or be pathogenic.

Resistance conferred by reduced intercellular concentrations of antibiotics is achieved by
efflux of the drug out of the cell and changes in cellular permeability reducing passive
diffusion of the drug through the cytoplasmic membrane. In addition to mutational
resistance, fluoroquinolones are also prone to resistance via efflux. NorA, an endogenous
efflux system in S. aureus, can be over-expressed reducing the effective concentration
within the cell to sub-lethal levels; inhibition of the efflux system can restore susceptibility
11

to these antibiotics. The overexpression of the efflux system is due to the accumulation of
mutations in the gene’s promoter sequence39.

1.3b Plasmid Acquired Resistance Determinants
The ease with which bacteria transfer genetic elements from one species to another via
plasmid genetic elements is responsible to the wide spread distribution of highly resistant
genes. Once acquired by the cell, the genes encoded within genetic elements can be
integrated into the chromosomal DNA through the process of horizontal gene transfer,
although some plasmids contain mechanisms that allow gene expression without
genomic incorporation. This mechanism of genetic material transfer is responsible for the
introduction of innately resistant, drug modifying and enzyme modifying enzymes31.

Resistance to methicillin and other beta-lactams in MRSA is conferred by the presence of
a penicillin-resistant penicillin binding protein (PBP2a), encoded by the mecA gene. βlactam antibiotics target the transpeptidase domain of endogenous penicillin binding
proteins (PBPs) involved in bacterial cell wall synthesis. PBPs are essential to bacterial
survival and the maintenance of cell wall integrity by acting as transpeptidases, crosslinking adjacent glycan strands in the cell membrane. PBP inhibition, via acylation by the
β-lactam ring, halts cell wall synthesis while peptidoglycan autolysis continues and
creates a compromised cell wall. The cells succumb to osmotic pressure, resulting in cell
death40.

PBP2a has low affinity for beta-lactam antibiotics allowing for uninterrupted

transpeptidase activity in the presence of high beta-lactam concentrations. The mecA
gene found on the SCCmec genetic element, is common in all MRSA strains and is
required for its ‘Methicillin resistant’ designation41. The acquisition of innately resistant
target enzymes is also responsible for antifolate resistance (Chapter 1.3c).
12

Additional beta-lactam resistance in S. aureus and other bacterial species is
accomplished by the acquisition of β -lactamase enzymes. β-lactams bind β-lactamases
and the nucleophilic active site acylates the β-lactam ring via a ring opening reaction.
Once acylated, an active site water molecule hydrolyzes the acyl bond and the cleaved,
deactivated β-lactam antibiotic is released from the active site
which deactivates the antibiotics by cleaving the lactam ring through an acylation
mechanism, releasing an inactive form of the drug42. Similarly, plasmid-acquired enzymes
can deactivate both macrolides and aminoglycosides.

For example, bifunctional

aminoglycoside deactivating enzymes, such as AAC(6’)-APH(2”), have both acetyl
transferase and phosphotransferase activity and have broad specificity towards the entire
class of aminoglycosides43. These enzymes add acetyl and phosphate groups to specific
alcohol substituents, reducing the affinity to its target, the 30S Ribosomal subunit.
Similarly, mph isoforms phosphorylate a narrow spectrum of macrolid antibiotics such as
erythromycin, which also targets the ribosome44.

In addition to modification of macrolides by phosphorylation, erm enzymes, most
commonly ermA, ermB, ermC, act as rRNA ribosomal methylases. These genes
methylate the 23S ribosomal macrolide binding site, reducing the affinity between the
inhibitor and binding site without sacrificing ribosomal function. The erm genes are
inducible and affect a broader spectrum of macrolide antibiotics than the macrolide
phosphorylase enzymes including erythromycin, azithromycin and clindamycin. These
genes are also more common than the macrolide modifying enzymes in the clinic45.
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Resistance can also be conferred by biological changes to the target. For example,
resistance to vancomycin, a first line antibiotic for complicated CA-MRSA and HA-MRSA,
is conferred by changes in the cytoplasmic membrane. Vancomycin and other
glycopepetides such as daptomycin bind the carboxy terminal of the D-Ala-D-Ala
disaccharide penyapeptide cell wall precursor during peptidoglycan synthesis, blocking
access for the transpeptidases required for cell wall generation. Resistance to
vancomycin is conferred by the acquisition of a cluster of van genes that produce D-AlaD-Lac disaccharides that are incorporated into the cell wall instead of D-Ala-D-Ala,
drastically reducing the affinity of vancomycin46. While still rare, vancomycin-intermediate
and vancomycin-resistant MRSA pose potentially devastating clinical consequences, as
the treatment options for these strains are already very limited.

1.3c Antifolate Resistance
TMP/SMX resistance in S. aureus began to arise in the 1980s following its clinical
introduction in 196847-49. In the 1990s, two TMPR mechanisms were identified as
conferring clinical TMP resistance: point mutations in the endogenous DHFR gene, dfrB,
and the acquisition of an innately resistant DHFR enzyme. A panel of point mutations, in
both the allosteric and active sites of the enzyme, resulted in moderate to high-level
resistance depending on the identity of the mutation. Noteworthy in this group was a Phe
to Tyr mutation at the 98th position that was isolated both alone and in combination with
other minor, allosteric mutations. Alone, the F98Y mutation conferred up to 400-fold loss
of affinity between TMP and the enzyme but the presence of H149R or H30N mutations
contributed to even greater losses in activity. An interesting compensatory relationship
between the two mutations suggested that the accumulation of the second mutation
increased the fitness of the enzymes in addition to increasing its resistance48.
14
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Figure 4 The chemical structures of trimethoprim and sulfamethoxazole.

In addition to point mutations within the target, a horizontally transferred, plasmidencoded resistant DHFR enzyme also appeared. The translated protein of the dfrA gene,
often called S1 (but will be called DfrA here for clarity), was observed to confer high levels
of TMP resistance at the enzyme level47. DfrA has three mutations in comparison to the
TMP-sensitive S. epidermidis DHFR: V31I, G43A and F98Y; where F98Y is the major
resistance determinant. The exact role of the F98Y mutation in TMP resistance is
unknown, however studies suggest that it disrupts or destabilizes the binding of NADPH
reducing its synergy with TMP, which is crucial for its potent activity47. More recently, two
additional plasmid acquired TMPR genes, dfrG and dfrK, have been identified. Both of
these genes, which are genetically similar, confer high levels of TMP resistance and
appear to be highly mobile as they have also been isolated in many Staphylococci,
Streptococci and Enterococci species50. Not only has no recent survey of TMPR MRSA
isolates from US hospitals identified common molecular mechanisms of resistance, but
the contribution of dfrG and dfrK was highly negated as clinically relevant despite
reports51. Resistance for both pemetrexed and methotrexate has also been reported as a
response to their use as anti-cancer agents. For pemetrexed, up-regulation of both
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thymidylate synthase and dihydrofolate reductase have been reported52,53. Much more is
known about methotrexate resistance, including decreases in active drug transport due to
changes in the reduced folate carrier (RFC), efflux out of the cell, and up-regulation of
DHFR29.

1.4 Small Molecule Therapeutics to Overcome Drug Resistance
Exploiting new antimicrobial targets would temporarily reduce the clinical burden of drug
resistant bacteria. However, no major classes of antibiotics have been discovered since
the late 1980’s, despite the introduction of linezolid and daptomycin in the early 2000’s54.
Efforts to overcome clinical antibiotic resistance are crucial for the continued, efficacious
treatment of these infections. These efforts include the development of next generation
inhibitors that are able to directly target the resistance mechanism and that are less
susceptible to developing resistance. In order to accomplish this, a comprehensive
understanding of the current and potential molecular mechanisms of resistance, through
structural models and biochemical evaluations, is applied to the iterative process of
development and evaluation.

Of the common mechanisms of resistance, only efflux, enzymatic modification and target
mutations can be modeled using protein crystallography. Efforts to utilize crystal
structures of efflux pump systems aim to elucidate the structural basis of substrate
specificity, knowledge of this can lead to the design on inhibitors that are less susceptible
efflux mediated resistance. Perhaps the two most successful examples of drug design to
overcome resistances is the development of fluoroquinolones to overcome mutational
resistance and β -lactam antibiotics that evade deactivation by β -lactamases.

16

1.4a Modification of the drug: β -lactamase enzymes
β-lactam antibiotics, including penicillins, cephalosporins and carbapenems (Figure 2a),
have a broad spectrum of activity and are often used as a staple of therapy in clinically
relevant infections caused by both Gram-positive and Gram-negative bacteria.
Resistance to this class of antibiotics, primarily through drug modification via βlactamases, has become a major barrier to effective treatment40.

Figure 2: a. Beta-lactam antibiotic structures and imipenem, the first clinically available
carbapenem antibiotic. Crystal structures of imipenem bound to b) TEM-1 (PDB: 1BT5,
magenta) and c) AmpC (PDB: 1LL5, blue) beta-lactamases.

There are four different classes of β-lactamases based on structural homology. Classes
A, C and D β-lactamases employ a nucleophilic serine to acylate the β-lactam bond while
Class B uses a Zn2+ ion in the active site55. As β-lactamases have a high degree of
structural homology to the PBPs, β-lactam antibiotics exhibit high affinity for these
enzymes. Extended-spectrum β-lactamases (ESBLs), mainly from Class A, arose from
early β-lactam use and are active in certain Gram-negative bacteria. ESBLs inactivate
cephalosporin antibiotics that are typically resistant to acylation via β-lactamases.

Among the β-lactam antibiotics that are not susceptible to deactivation by serine βlactamases is a class of antibiotics called carbapenems55. Structurally, carbapenems
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have a similar 4-5 fused ring scaffold as penicillins differing by carbon substitution at the
C1 position and a double bond at the C2-C3 position of the pyrroline ring (Figure 2). Of the
clinically relevant β-lactams, carbapenems have the greatest potency and broadest
spectrum of activity towards Gram-negative and Gram-positive bacteria56. Carbapenems
act as β-lactamase inhibitors and are thus inherently resistant to deactivation by βlactamases. Imipenem, the first clinically available carbapenem, binds the β-lactamase
active site with high affinity and like other β-lactam antibiotics becomes acylated.
However, owing to a slow rate of hydrolysis, imipenem acts more as an inhibitor than a
substrate. A crystal structure of imipenem bound to TEM-1, a Class A β-lactamase (PDB:
1BT5) and AmpC, a Class C β-lactamase (PDB:1LL5) captures the acyl intermediate that
is key to its action as a β-lactamase inhibitor (Figure 2). The structures show the 6α-1Rhydroxyethyl substitutions on the β-lactam ring cause the ligand to adopt an unexpected,
strained conformation once bound to the enzyme. This strained conformation displaces
the hydrolytic water in the active site, protecting it from deacylation55-57.

Discovery of newer generation carbapenems is critical in order to overcome emerging
resistance by Class B β-lactamases and the metabolic instability of imipenem. Imipenem
is susceptible to elimination via dehydropeptidase-1 (DHP-1) found in the renal tubules,
requiring the co-administration of a DHP-1 inhibitor to improve stability. Doripenem, a
later generation carbapenem, corrects for imipenem’s metabolic instability, increases its
Gram-negative bacterial activity and has reduced β-lactamase susceptibility56. In addition
to overcoming metabolism by DHP-1, attempts have been made to overcome resistance
to Class B, metallo-β-lactamases. This has proven to be difficult, although strides have
been made using the carbapenem transition state as a basis for novel beta-lactamase
inhibitors. Additionally, crystal structures of metallo-β-lactamases, such as the recently
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published New Delhi metallo-β-lactamase, will aid the design of inhibitors. Other
motivating factors for new carbapenem discovery include overcoming lowered PBP
affinity due to point mutations, resistance due to efflux, and issues overcoming poor
cellular penetration57.

1.4b Modification of the Target: Binding Site Mutations
Mutations in the target protein that reduce the affinity between the drug and protein may
arise by selection in the presence of drug pressure. The mutations may occur in the first
shell of residues that contact the drug and eliminate key contacts or may arise in the
outer shell and affect the conformation or dynamics of the drug-binding site. If mutations
in the drug target is a mechanism by which resistance arises for a given drug, it is
possible to determine the structures of both the wild type and mutated (resistant) proteins
in order to understand the basis of resistance and allows for a modeling approach to
predicting and overcoming the loss of interactions.

Bacterial

topoisomerases,

including

DNA

gyrase

(topoisomerase

II)

and

DNA

topoisomerase IV, are the target of quinolone antibiotics and are essential for replication.
The topoisomerases have formed a successful platform for drug discovery for the past
several decades, beginning with the discovery of the Gram-negative antibacterial activity
of nalidixic acid37. Over the years, there have been several generations of quinolone
antibiotics, with notable examples including ciprofloxacin, levofloxacin and moxifloxacin58.
Each generation of quinolones has expanded the spectrum of coverage of these
compounds to include Gram-negative and -positive bacteria, Pseudomonas and
Mycobacterium tuberculosis58. The primary mechanism of resistance to fluroquinolones
in S. aureus is a stepwise accumulation of mutations in grlA, grlB and gyrA. High levels of
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resistance are often achieved through mutations in the target combined with up regulation
of efflux pump activity, for example norA in S. aureus. Crystal structures of Acinetobacter
baumanii

59

or Streptococcus pneumonia60 topoisomerase IV bound to DNA and

moxifloxacin have revealed many of the details of the mechanisms of topoisomerases,
the mode of inhibition of the quinolone antibiotics and the structural basis of quinolone
resistance.

Figure 3. a) Chemical structures of moxifloxacin and GSK299423 b) The crystal structure
of gyrase (purple) bound to DNA (backbone shown in orange) and two copies of
GSK299423 (cyan) from PDB ID: 2XCS61. The figure shows a superposition of
moxifloxacin (green) from PDB ID: 3FOF60. Typical resistance mutations are shown in
magenta.

In response to the observed resistance to quinolones, several groups have worked to
design more effective molecules that are active against the resistant strains. For example,
scientists at Glaxo Smith Kline designed compound GSK299423 to act via a mechanism
distinct from the quinolones based on stabilization of a pre-cleavage enzyme-DNA
complex61. Structures of GSK299423 show that the compound occupies a novel noncatalytic binding pocket between the two GyrA subunits, which is adjacent to but not
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overlapping with the ciprofloxacin site. As such, the affinity of the compound is not
affected by the existing resistance mutations. In fact, GSK299423 shows potent activity
against several bacterial strains, both wild-type and fluoroquinolone-resistant.

1.5 Conclusions
Staphylococcus aureus and its notorious ability to evolve and evade antibiotic pressure
by the development of antibiotic resistance presents a major clinical burden. With the rise
of community acquired MRSA strains and the continual decrease in therapies, MRSA has
resulted in increased mortality, morbidity and costs associated with the onset of
infections. Antifolates are crucial for the efficacious treatment of these infections,
specifically the combination of TMP/SMX. However, its continued use is threatened by the
development of diverse resistance mechanisms.

In this work, we present the development of a novel class of antifolates to overcome
trimethoprim resistance; predicting, inducing and identifying the molecular mechanisms of
resistance to the experimental and clinical antifolates. Understanding the interactions
between the drug and target, through resistance, not only allows for the rational
development of potent inhibitors against the resistance determinants but inhibitors that
are also less susceptible to resistance. In doing this, we have identified two major lead
scaffolds that show superior activity against TMPR enzymes derived from the iterative
process of structure based drug design.
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Chapter 2
Development of Propargyl-linked Antifolates as Potent Antimicrobial Agents

2.1 Evolution of Propargyl-linked Antifolates from Trimethoprim
Antifolates are important agents for continued anti-cancer and anti-microbial treatments.
Trimethoprim is a well-tolerated, inexpensive antibiotic with a broad activity against grampositive, gram-negative and parasitic diseases. However, the development of resistance
and prevalence of innately resistant pathogens limits the use of this therapeutic. Efforts to
develop a new class of antifolates against these clinically important and resistant disease
states attempt to combat these problems. The development of this class of antifolates
employed the iterative process of structure based drug design, in which high resolution Xray structures of the protein:inhibitor complex are used to guide inhibitor design. Rational
modifications to the inhibitor scaffold, based on the interpretation of the crystal structures,
are tested in-vitro to validate or reject the design principle1. Ultimately, this method should
result in the development of selective, potent inhibitors optimized against its target.

Crystal structures of trimethoprim in complex with Cryptosporidium hominis (C. hominis)
dihydrofolate reductase (Ch DHFR) revealed that the inhibitor’s poor fit into the active site
is responsible for its innate resistance. Evaluation of the Ch DHFR active site revealed a
narrow hydrophobic ‘tunnel’ leading to an unoccupied substrate-binding pocket.
Therefore, a series of TMP-like antifolates were developed to expand the distance
between the diaminopyrimide and trimethoxybenzyl rings and extend the inhibitor further
into the active site to accumulate hydrophobic interactions2.
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Modifications to the TMP structure and extension of the single methyl linkage include an
acetylene linker (Figure 1, Scaffold A) and ethylene linker including the cis- and transisomers as well as its saturated alkane counterparts (Scaffold B). However, the only TMP
derivative that gained activity against these parasitic DHFR enzymes contained a rigid
acetylene linker connected to the trimethoxybenzyl ring by a propargylic carbon (PLA
Scaffold)3. This scaffold, named for its propargyl linker, was further modified with alkyl
substitutions on the diaminopyrimidine ring and propargylic position resulting in a series
compounds with nanomolar activity against the enzyme.
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N
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Figure 1 TMP Derivatives Optimizing Linker Identities

Cryptosporidium hominis (C. hominis) is an opportunistic parasite that was a major cause
of morbidity in immunocompromised patients, specifically those with HIV. However, as
HIV diagnostics and therapies improved, the clinical impact of C. hominis decreased4 and
the focus of the development of Ch DHFR inhibitors shifted to gram-negative and grampositive bacteria as well as pathogenic fungal and mycobacterium species.
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The first generation PLAs were assessed against Bacillus anthracis, an innately TMPR
gram-positive bacteria that was feared as a tool of bioterrorism5. Crystal structures of the
PLAs in the Bacillus anthracis dihydrofolate reductase (Ba DHFR) active site shows the
acetylene fitting through the narrow hydrophobic tunnel made of Phe 96 and placing the
trimethoxybenzyl ring in the hydrophobic, substrate binding pocket, as designed.
Additional analysis of the structures indicated that further alkyl substitutions at the C6
position on the diaminopyrimidine ring, specifically an ethyl substituent; exploits
interactions with an active site valine (Val 32) and leucine (Leu 29) residue. This work
concluded that increased potency and selectivity over human DHFR can be achieved by
adding bulky substitutions at the meta-position of the trimethoxybenzyl ring to increase
contacts within the substrate binding site6. This revelation lead to the development of the
second generation of propargyl-linked antifolates that feature an ethyl substituted
diaminopyrimidine linked to the meta-substituted biaryl system by an acetylene linker
(Figure B). The proximal B-ring and distal C-rings can be substituted with both
heterocycles or aromatic rings as well as small alkyl or polar substituents, allowing for
further optimization and establishment of a structure activity relationship.
Acetylene
Linker
RP
NH 2
Diaminopyrimidine
Moiety

N
H 2N

B
A
N

Biaryl
System
C

Figure 2 Second Generation PLA Scaffold
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The second generation of propargyl-linked antifolates explored different C-ring
substituents. Inhibitors with a distal benzyl or dimethyl benzyl were evaluated against
wild-type S. aureus DHFR (DfrB) and a quality control S. aureus strain (ATCC 43300).
The series of compounds with these hydrophobic C-rings exhibited very potent (3-80 nM)
enzymatic potency and MICs below 100 ng/mL7. Crystal structures of this series validate
the design principles of building these compounds into the substrate-binding pocket. The
structure showed the standard polar interactions between the active site and
diaminopyrimidine ring as well as hydrophobic interactions with Val 31 and stacking
interactions between the acetylene linker and Phe 92 side chain.

The biaryl system

picked up extensive side chain Leu 20, Leu 28, Ile 50 and Leu 54 contributing to the
formation of stable, inhibitory complex with the distal ring pointed toward the solvent
exposed pocket of the enzyme. Unfortunately, this class of compounds displayed poor
solubility and potent activity against human DHFR and resulted in minimal selectivity with
over 70% of the inhibitors having a human/ S. aureus selectivity ratio of <10 7.

29

Figure 3 Crystal structure of a distal dimethylbenzyl substituted biaryl PLA bound to S.
aureus DHFR (3F0S) highlighting the extensive network of hydrophobic interactions
between the inhibitor and active site.

Replacement of the benzyl and substituted benzyl rings with heterocycles, namely 4pyridine, increased the selectivity, potency and solubility of the class (Section 2.2). The
biaryl compounds showed increased potency against a panel of gram-positive bacteria,
including Staphylococcus aureus and Streptococcus pyogenes7 as well as gram-negative
bacteria8 and fungal species Candida albicans and Candida glabrada9,10. This class of
compounds was also used as probes to explore the importance of stereochemistry at the
propargylic position (Section 2.3). A third, and current, generation of PLAs were further
optimized by the addition of a para-carboxylate meant to form ionic interactions with polar
amino acids in the distal region of the substrate-binding site, this class of compounds is
described in Section 2.4.
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2.2 Pyridine PLAs as a Promising Lead Scaffold
The meta-pyridine biaryl PLA scaffold was the first promising lead series within the class
against S. aureus DHFR. The evolution of the propargyl linked antifolates from single aryl
trimethoprim derivatives to hydrophobic, bulky meta-biphenyl compounds illustrates how
this class of compounds can be optimized as potent DHFR inhibitors. The further
incorporations of C-ring heteroatoms to the biaryl

RP

scaffold increased potency, solubility and selectivity.
Identifying 4-pyridyl PLAs as a second-generation
lead scaffold provides an opportunity for continued H 2N
development and optimization by exploring various RP

R1

NH 2

R2

N

R3
N
N

and B-ring substitutions (Figure 4)7. The second- Figure 4 Pyridine PLA Scaffold
generation pyridine class of PLAs can be divided into three major scaffolds: monomethoxy substituted, di-methoxy substituted and a rigid dioxolane, fused ring scaffold.

2.2a Methoxy-substituted PLAs
Compounds with single substitutions at the R1 and R2 positions were synthesized with
and without alkyl substitutions at the propargyl position (RP), evaluated for both cellular
and enzymatic activity, establishing a structure activity relationship. The R1 substituted
compounds show a 32-fold difference in cellular activity when comparing the propargyl
hydrogen (UCP1021) and the propargyl methyl (UCP1040) with MICs of 0.0195 µg/mL
and 0.625 µg/mL but show very similar enzymatic activity with IC50 values of 21nM and
30nM, respectively (Figure 5). The addition of the propargylic methyl creates a single
stereocenter in the inhibitor, which could account for the loss off activity seen with
UCP1040, as single enantiomer inhibitors are known to display differential activity against
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its enzymatic target11. The importance of the stereochemistry at this position was
explored and discussed in Chapter 2.3.
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IC 50: 12 +2 nM

MIC: 0.0781 µg/mL
IC 50: 19 +1 nM

Figure 5 Methoxy-substituted PLAs with Cellular and Enzymatic Activities

Moving the methoxy from the R1 to the R2 position only resulted in minimal losses in
cellular activity, with MICs increasing from 0.0195 to 0.0781µg/mL with a RP hydrogen
substitution (UCP1015). However incorporation of a methyl at this position, in
combination with the R2-methoxy (UCP1006), results in no MIC shift when compared to
UCP1015, however it gains 8–fold activity over its R1-methoxy equivalent. Similarly, the
IC50 values for these compounds are almost indistinguishable at 19nM and 12nM for
UCP1006 and UCP1015 (Figure 5)7.

Previously published crystal structures indicate an extensive network of hydrophobic
interactions between the pyridine PLA and the DHFR active site, in addition to the
hydrogen bonding interactions of the diaminopyrimidine moiety to an active site water,
side chain of Asp 27 and backbone carbonyls of Leu 5 and Phe 92. The aromatic Phe 92
side chain makes additional stacking interactions with the acetylene linker and the side
chains Leu 28 and Val 31 make additional hydrophobic interactions with the C6-ethyl on
the diaminopyrimidine. Ile 50 and Leu 54 side chains make extensive interactions with the
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biaryl system whose pyridine ring is oriented towards the solvent exposed area of the
active site. Finally, the propargyl methyl appears to make hydrophobic interactions with
the nicotinamide ring of NADPH (Figure 6).

Figure 6 DfrB (purple) complexed with NADPH and UCP1006 (blue) highlighting the
hydrogen bonding and hydrophobic interactions between the inhibitor and active site,
PDB ID: 3SGY.

2.2b Dimethoxy and Dioxolane Substituted PLAs
Single methoxy B-ring substitutions on the pyridine scaffold afford potent activity against
wild-type MRSA (ATCC 43300) and DHFR enzyme (DfrB). Trimethoprim contains three
methoxy B-ring substituents proximal to the hydrophobic active site, accumulating weak
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interactions that result in potent, broad-spectrum activity. Increasing and exploiting these
hydrophobic interactions can further optimize the pyridine PLAs and increase potency
against the DHFR targets. To probe this hypothesis, a series of pyridine PLAs with
dimethoxy substituents (R1/R3 and R2/ R3 substituted) pyridine PLAs were synthesized
and evaluated. The series of compounds also features compounds with a benzodioxolane
fused ring system at the R1/R2 and R2/R3 positions revealing a SAR between dioxolane
positions as well as propargyl substitutions.

Pyridine PLAs with methoxy substituents at the R1/R3 and R2/R3 were synthesized and
evaluated, the latter scaffold with and without substitutions at the RP position. With RP
hydrogens, moving the second methoxy from the R1 (UCP1033) to R2 (UCP1039)
positions resulted in a 16-fold increase in both cellular and enzymatic activity with MICs of
0.3125 µg/mL to 0.0195 µg/mL and IC50 values of 202 nM and 14 nM, respectively (Figure
7). The addition of the propargylic methyl to UPC1039 (UCP1082) resulted in an increase
in MIC to 0.3125 ug/mL, mimicking the MIC of the R1/R3 substituted and potentially
indicating that substitutions at the RP and R1 positions have similar effects in substrate
binding (Figure 7).
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Figure 7 Dimethoxy-substituted PLAs with Cellular and Enzymatic Activities
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This series was pursued further by constraining the dimethoxy substitutions via a
dioxolane ring resulting in a fused B-ring system that has reduced flexibility in the active
site. Even though substitutions at the R1 positions were not optimal for the dimethoxy
series, a single R1/R2 benzodioxone compound with an RP methyl was evaluated. This
compound exhibited poor cellular and enzymatic activity with an MIC of 0.625 µg/mL and
an IC50 of 4.2 µM. Shifting the dioxolane ring to the R2/R3 positions (UCP1038) reduced
the MIC to 0.0781 µg/mL and IC50 value to 17nM. Furthermore, removal of the RP-methyl
raised the MIC to 0.3125 µg/mL but left the IC50 unaffected while the introduction of two
RP-methyl substituents further increased the MIC to 0.625 µg/mL (UCP1072, Figure 8).
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Figure 8 Dioxolane-substituted PLAs with Cellular and Enzymatic Activities

Because dioxolane rings are a known metabolic liability, as the acetal can form
covalent bonds to the heme of CYP enzymes a RP methyl, R2/R3 dioxolane with
deuterium at this position was synthesized (UCP1070)12. When trying to avoid metabolic
or other pharmacokinetic liabilities, deuterium, which mimics hydrogen in size and
chemical properties, can substitute hydrogen atoms and mitigate these reactivities13. The
addition of the deuterium to the dioxolane ring resulted in no loss of activity when
compared to its hydrogenated counterpart (UCP1038).
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Figure 9 The crystal structure of a) DfrB:NADPH:UCP1070 (blue) and b)
DfrB:NADPH:UCP1070 (blue) superimposed with DfrB:NADPH:UCP10067 (purple). The
amino acids that form interactions with specific binding modes are the same color as the
corresponding inhibitor.

A 1.47Å crystal structure of UCP1070 complexed with DfrB reveals two distinct
conformations of NADPH and binding positions of the biaryl system. The two binding
modes could be a result of the capture of the single enantiomers within the racemic mix,
where as one inhibitors binds in the same orientation observed in Figure 6 and the other
occupies a more solvent exposed binding pocket of the active site (Figure 10b). The
structure reveals distinct hydrophobic interactions between the two binding modes where
Ile 50 maintains contact with both but one inhibitor position forms interactions with Leu 54
(blue) and the other picks up interactions with Leu 20, located on a flexible loop region of
the active site (pink, Figure 9). The additional interactions made between dioxolane ring
and Leu 20 and Ile 50 side chains may contribute to the superior potency of the dioxolane
and dimethoxy-substituted compounds, validating this attempt to further optimize the
class of PLAs. The relevance and implications of the variable and novel NADPH
configurations seen in Figure 9 are discussed in depth in Chapter 2.5.
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2.3 Enantiopure Propargyl-linked Antifolates
Some of the most potent PLAs that have been evaluated against DHFRs of pathogenic
bacteria feature a methyl substitution at the propargyl position resulting in a single
stereogenic center6-10. Previous structural studies with a series of PLAs show that these
branched substituents are proximal to the cofactor-binding site and may provide
compensatory interactions with NADPH as well as providing conformational control of the
biaryl ring system14,15. Therefore, investigating the role of the stereogencicity of the
propargyl center in governing the inhibitors activity becomes priority. Probing the role of
the configuration at the single stereocenter in these inhibitors required the preparation of
a series of non-racemic, branched PLA inhibitors. These inhibitors possess potent
enzyme inhibition (IC50 values <50nM), antibacterial effects (most MICS <1µg/mL) and
form stable ternary complexes with the cofactor and enzyme. Individual crystal structures
of a pair of enantiomers in S. aurues DHFR reveal that a single change in configuration of
the stereo-center drove both the binding orientation of the biaryl systems as well as the
selection of an alternative NADPH cofactor16.

2.3a Biochemical and Microbiological Evaluation of Enantiomers
The series of enantiopure inhibitors indicates that the compounds maintain strong
inhibition of wild-type S. aureus DHFR (DfrB) with the majority of inhibitors having IC50
values less than 50nM (Table 1). The compounds also display significant antibacterial
activity against a quality control strain of MRSA (ATCC 43300) with the most active
enantiomers showing an 8-fold increase in activity over trimethoprim. In contrast to TMP,
the PLAs were designed to form alternative and additional contacts with residues in the
active site by the biaryl domain and branched at the propargylic position to become less
dependent on synergy with the cofactor. Interestingly, varying degrees of antibacterial
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activity were observed within the pairs of enantiomers. For example, the MICs of the Rand S- R1 methoxy substituted inhibitors (UCP1061 and UCP1062) differed 8-fold with
values of 0.3125 µg/mL and 0.0391 µg/mL, respectively. Similarly, the R- and S-R2
methoxy inhibitors (UCP1064 and UCP1063) have MIC values of 1.25 µg/mL and 0.078
µg/mL, a 16-fold difference in antibacterial activity. Conversely, the R3 methoxy
(UCP1096/UCP1097), dioxolane (UCP1098/UCP1099) and R2 ,R3-dimethoxy (UCP1079/
UCP1080) substituted compounds only had a 2- or 4-fold discrepancy in MIC values
(Figure 10, Table 1).
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Figure 10 Structures of Enantiopure PLA compounds
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Table 1 Biological activity of Enantiopure PLA compounds
Sa MIC

DfrB IC50 a

DfrB IC50 b

NADPH Rate

Thy+ Sa MIC

(μg/mL)

(nM)

(nM)

(μM/min)

(μg/mL)

UCP1061 (R)

0.3125

15.0 + 0.7

69 + 5

-0.919

5

UCP1062 (S)

0.0391

18+ 2

155 + 5

-0.965

5

UCP1063 (S)

0.0781

11 + 0.7

37 + 5

-0.454

5

UCP1064 (R)

1.25

19 + 1

464 + 27

-4.571

10

UCP1079 (R)

1.25

46 + 4

26 + 3

-0.850

10

UCP1080 (S)

2.5

74 + 6

98 + 8

-2.712

>20

UCP1096 (R)

1.25

202 + 20

458 + 37

-19.944

10

UCP1097 (S)

0.3125

35 + 6

211 + 12

-0.428

10

UCP1098 (R)

0.3125

46 + 6

78 + 4

-1.241

5

UCP1099 (S)

0.0781

35 + 2

45 + 6

-0.359

10

TMP

0.3125

23 + 3

77+4

-0.505

>20

Inhibitor

a
b

Measured with 5 minutes pre-incubation of enzyme and inhibitor
Measured with no pre-incubation of enzyme and inhibitor

As antibacterial activity is highly dependent on the degree and persistence of the
blockade of the essential targeted pathway, we investigated the target inhibition profile of
the enantiomers with DHFR. By comparing enzyme inhibition values using the standard
incubation of enzyme and inhibitor (5 min)7 with those that did not have the pre-incubation
step, we attempted to detect differences in the capacity for the enantiomers to quickly for
a stabled, inhibited complex. The results show an increase in the observed IC50 values
with the magnitude of increase depending on the specific pairs. For example, the
dioxolane derivatives (UCP1098/ UCP1099) display on marginal increases in IC50 value
while the R2-methoxy derivative (UCP1063) shows a more substantial increase in
observed IC50 (24.4-fold) as well as a more significant difference between the two
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enantiomers (3.4 vs. 24.4-fold). Overall these experiments suggest that some inhibitors
require the pre-incubation step in order to form a high affinity complex.

Rates of dissociation of the complexes were also determined for five pairs of
enantiomers. Dissociation, in which the inhibitors and the enzyme were incubated with
the enzyme for 18-24 hours prior to activation with the substrate, was determined to
further understand the stability of the tertiary complex17. The enzymatic reaction,
measured by the rate of oxidation of NADPH, was monitored over an hour period and the
differential rate of dissolution of the complex was determined for each enantiomer pair.
Overall, the target inhibition profile experiments show that inhibitors, UCP1063,
UCP1079, UCP1080, UCP1098 and UCP1099 appear to form an inhibited complex
quickly. Furthermore, several inhibitors including UCP1061, UCP1062, UCP1063,
UCP1079, UCP1097 and UCP1099 have a relatively show rate of dissociation of this
complex (Table 1 and Figure 11). As effective antibacterial agents must quickly form a
long-lasting and effective inhibitory complex with the target, these results are promising,
especially for UCP1063 and UCP1099, as these compounds possess both of these
characteristics.
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Figure 11 Dissociation of the inhibitory complex (DfrB:NADPH:PLA) over a 60 minutes
reaction period following 18 hours of incubation. Differences of dissociation rates indicate
the differences in stability of the complex attributing to antimicrobial effects.

The potential of the enantiomers to possess differential affinity to an unknown second
target, resulting to increased antibacterial activity, was probed by end-product rescue
experiments. As the PLAs are inhibitors of the folic acid biosynthetic pathway, which is
primarily responsible for the production of deoxythymidine monophosphate, rescue
experiments were conducted to measure MIC values in the presence of excess thymidine
(Thy+)18. With 10 μg/mL thymidine, MIC values rose to 5-10 μg/mL indicating on-target
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activity (Table 1). Thy+ MICs that increase less than 8-fold indicates inhibitory activity
against a target outside of the folic acid cycle. It is not believed that differences in
enantiomer activity are due to preferential permeability or efflux, as the physiochemical
properties of the enantiomers are identical16.

2.3b Structural Studies of an Enantio-pure Pair of Inhibitors
Crystal structures of DfrB complexed with UCP1061 and UCP1062 reveal unexpected
and significant differences in the binding mode of the two enantiomers with the enzyme.
After collection of diffraction data (2.69Å and 2.16Å, respectively) the structures were
determined by molecular replacement with probe molecule PDB ID 3F0Q10. The structure
of DfrB:NADPH:UCP1062 is identical to the previously reported structure of S. aureus
DHFR crystallized with its racemic counter part, UCP1006 (Figure 6)7, suggesting that the
ternary complex with UCP1062 is more thermodynamically stable complex relative to that
formed with UCP1061. In the structure of DfrB:NADPH:UCP1062, the enzyme binds the
extended, β-form of NADPH with a number of key van der Waals contacts between the
inhibitor and the nicotinamide ring of the cofactor involving each of the four carbons of the
propargyl linker. In addition to the expected interactions between the diaminopyrimidine
and residues Asp 27, Val 31 and Leu 28 there are contacted between Leu 28, Ile 50, met
42 and Leu 54 and the hydrophobic pyridine C-ring favors a coplanar arrangement with
its joined B-ring (Figure12).

The structure of DfrB:NADPH:UCP1061 reveals a major change in both biphenyl binding
mode and NADPH cofactor binding where the nicotinamide and ribose rings are
displaced approximately 3.2Å relative to the standard β-NADPH anomer, a result of the
puckering of the internal phosphates. In this alternative NADPH structure, as seen in the
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DfrB:NADPH:UCP1070 structure (Figure 9), the caboxamide forms three water-mediated
hydrogen bonds to the protein rather than the direct hydrogen bonding interactions with
Ala 7 (Figure 12b). Despite this displacement, the pyrophosphate tail and adenine
nucleotide are ultimately placed in the identical binding positions14,15. The significance and
impact this alternative NADPH is discussed in-depth in Section 2.5.

Figure 12 Crystal structures of wild-type S. aureus DHFR (DfrB) bound to cofactor and
inhibitors: a) compound UCP1062 (teal) and β-NADPH (salmon) or b) compounds 1061
(purple) and α-NADPH NADPH (orange). Panel C shows a superposition of the two
structures.
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Aside from NADPH, Ile 50 undergoes a second significant conformation change in order
to accommodate the differing enatiomeric preference. Both a 1.5Å displacement of the
protein backbone and a change of the side chain rotamer of Ile 50 are necessary to
accommodate the R-configuration of UCP1061. Therefore, when a racemic mixture of the
ligand is present, the protein would need to undergo a significant conformation change to
binding the opposite enantiomer.

Evaluation of 5 pairs of enantiopure PLAs in the effort to further optimize the scaffold
towards efficacious inhibition of S. aureus emphasizes the importance of substitutions,
specifically the stereochemistry of substitutions at this propargylic position. Biochemical,
microbiological and structural analysis indicates differences in binding orientations,
cofactor recruitment, and the stability of the inhibitory complex; each contributing to
differing antibacterial activities between enantiomer pairs. This work highlights the
importance of pursuing enantiomerically pure inhibitors as we continue to modify and
optimize the series.

2.4 Charged Propargyl-linked Antifolates
Classical antifolates, such as methotrexate and pemetrexed, mimic substrate structure
and exhibit sub-nanomolar affinity for eukaryotic and prokaryotic DHFR enzymes.
However, these compounds lack bacterial efficacy due to insufficient permeability into the
cell, a result of its highly charged nature20-22. These classical antifolates, marketed as
potent chemotherapeutic, are actively transported into eukaryotic cells through folic acid
transporters, but because bacterial cells produce folic acid de novo, they do not possess
the mechanisms required for uptake. Methotrexate’s high affinity for the enzyme is
credited to the ionic interactions formed between the enzyme and the glutamate tail of the
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compounds23 (Figure 13). Similarly, the superior activity of the pyridine PLAs over TMP is
attributed the increase of interactions between the inhibitor and enzyme. However,
building onto the PLA scaffold by the addition of a C-ring carboxylate to mimic that of
methotrexate and folic acid to pick up ionic interactions with an active site argenine
residue and further optimize the inhibitors.

Figure 13 SaDHFR complexed with β-NADPH and a) folate (blue, PDB:3FRD) and
UCP1061 (magenta) a pyridine substituted and b) UCP1191(light blue) a carboxylate
substituted PLA. The ionic interaction acquired through the addition of the C-ring
carboxylate is highlighted in panel B.

In addition to the acquisition of a hydrogen bonding interaction between the inhibitor and
the protein, the introduction of charged character to the PLAs is expected to increase
permeability of the compounds into gram-negative bacteria, namely Escherichia coli and
Klebsiella pneumonia. The absence of PLA activity against these pathogenic strains is
attributed to the lack of passive diffusion through the thick peptidoglycan outer membrane
of

these

pathogenic

species8.

Fluoroquinolones,

specifically

ciprofloxacin,

and

tetracyclines have potent activity against these gram-negative bacteria, their ability to
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penetrate the membranes and accumulate in the cell is attributed to the zwitterion
character of a single carboxylic acid23. In order to explore these hypotheses, we
developed a series of compounds that features a phenyl C-ring with carboxylic acid
substitution and varying B-ring and propargylic substitutions (Figure 14). While the
addition of zwitterionic character did not increase activity in gram-negative species, with
the most potent compounds having a MIC of 10 µg/mL24, ventures to improve the proteininhibitor interactions were successful.

2.4a Biological Evaluation of COOH-PLAs against S. aureus
UCP1106, a para- carboxylate substituted PLA with an R1-methoxy, was the first
compound of the series to be evaluated revealing very promising cellular and enzymatic
activity in wild-type S. aureus. The role of the carboxylate placement was explored and
optimized within the series, by synthesizing and evaluating the ortho- (UCP1133) and
meta- (UCP1124) substituted analogs (Figure 14, Table 2). Migration of the carboxylate
from the para- position to both the meta- and ortho- positions resulted in significant, 5and 12- fold decrease in cellular activity, with a rise in MIC from 0.0195 µg/mL to 0.625
µg/mL and >20 µg/mL, respectively.
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Figure 14 Structures of PLAs to determine COOH placement SAR
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The series of p-carboxylate compounds was further expanded with various B-ring and
propargylic substitutions. Moving the methoxy from the R1 (UCP1106) to the R2
(UCP1175) position resulted in a three-fold increase in enzymatic activity against
SaDHFR, from 32 to 11 nM, respectively. This modification also resulted in a 2-fold
decrease in MIC from 0.0195 to 0.0098 µg/mL. Meanwhile, the placement of the methoxy
group had little effect on activity against HuDHFR (Table 2)24, 25.

Evaluation of enatiopure PLAs is crucial for the continued optimization of the series of
COOH-PLAs, as the methyl configuration is important not only for its noncovalent
interactions but also for directing the binding position of the biaryl system16. The Senantiomer of UCP1106 (UCP1164) exhibits no significant change in IC50, unlike the Renantiomer (UCP1163) that has a 7-fold loss in enzymatic activity and 16-fold loss in
cellular activity with MICs of 0.625 µg/mL. The R2- methoxy enantiomers, inhibitors
UCP1172 (R) and UCP1173 (S), maintain similar activity as their hydrogen-substituted
counterpart (UCP1175), with MICs of 0.0098 µg/mL and IC50 values of 8.9 nM, 14 nM and
11 nM, respectively. Similarly, UCP1205 and UCP1206 and the racemate UCP1191 with
a constrained dioxolane ring at the R2 and R3 positions are nearly distinguishable by
activites with MICs of 0.0098 µg/mL and IC50 values of 18nM,17nM and 10nM,
respectively (Figure 15, Table 2).
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Table 2 Cellular and Ezymatic Evaluation of COOH-PLAs
Inhibitor

S. aureus

SaDHFR IC50

Hu DHFR

MIC (µg/mL)

(nM)

IC50 (μM)

UCP1106

0.0195

32 + 0.001

870 + 30

UCP1124

>20

359 + 0.03

10,800 + 200

UCP1133

0.625

157 + 0.008

1,580 + 60

UCP1163

0.625

37 + 2

1,630 + 90

UCP1164

0.0391

216 + 20

1,960 + 0.05

UCP1172

0.0098

9 + 0.7

1,020 + 0.06

UCP1173

0.0098

14 + 1

1,700 + 100

UCP1175

0.0098

11.0 + 0.6

690 + 40

UCP1191

0.0098

10.0 + 0.2

ND

UCP1205

0.0098

18 + 3

ND

UCP1206

0.0098

17 + 2

ND

TMP

0.3125

23 + 3

198.2 + 0.1

MTX

>40

ND

ND

p-COOH PLAs exhibits potent cellular and enzymatic activity against S. aureus MICs
values ranging from 0.0098-0.625 µg/mL (Table 2). Furthermore, inhibitors UCP1175,
UCP1172 and UCP1173 were shown to be bactericidal with minimum bactericidal
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concentrations (MBC) less than four times the MIC24,26. While this class of compounds
does not overcome barriers in gram-negative activity, as they were designed to, the
compounds are promising candidates for development against gram-positive species.

2.4b Structural Analysis of Charged PLAs in S. aureus DHFR
In order to understand the mechanisms of action and validate design principles, the X-ray
crystal structures of S. aureus DHFR bound to a panel of COOH-PLAs were determined.
Crystals of SaDHFR complexed with NADPH and inhibitors UCP1106, UCP1175 and
UCP1191 produced diffraction amplitudes to 2.24 Å, 1.81 Å and 1.88Å, respectively. All
structures were solved using molecular replacement using: PDB 3F0Q19 as a model. All
structures feature the COOH-PLA bound with full or partial occupancy of β-NADPH and
its alternative α-anomer in its cyclized, ring-closed tautomer. In all structures, the
diaminopyrimidine of the antifolate forms conserved hydrogen bonds with Asp 27 and
backbone carbonyl oxygen atoms from Leu 5 and Phe 92 (Figure 16). The propargyl
linker and benzodioxalane B-ring form hydrophobic interactions with Phe 92, Thr 46, Leu
28, Val 31 and Ile 50. The phenyl C-ring is positioned well to form hydrophobic
interactions with Leu 54, Val 31 and Leu 28.
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Figure 16 Active site views of a) UCP1106 and b) UCP1175 highlighting water network
formed between the inhibitor and enzyme and comparisons of c) the binding position of
the hydrogen substituted PLAs and d) the contrasting NADPH conformations

The UCP1106 complex shows the coordination of a water molecule between the
carboxylic acid (2.1Å) and the side chain of Arg 57 (2.8Å) (Figure 16a). Conversely, the
structure with compound UCP1175 exhibits an extensive water network involving at least
four water molecules, coordinated between the carboxylic acid and both amino groups on
Arg 57 as well as the carbonyl oxygen of Leu 28. The water network expands to include
additional hydrogen bonding interactions with the side chains of Asn 56 and Thr 36
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(Figure 16b). The binding modes of the inhibitor represent significant differences in the
crystal structures with inhibitors UCP1106, UCP1175 and UCP1191. The methoxy
substitution in the R1 position of compound UCP1106 shifts the biaryl system 1.2 Å
toward the solvent exposed surface, which is likely responsible for differences in the
observed water networks between compounds UCP1106 and UCP1175 (Figure 16c).

Crystal structures of UCP1191, reveals a potential basis for the increased cellular and
enzymatic potency of propargylic substituted PLA-COOH compounds. Importantly, the
carboxylate moiety forms one direct ionic bond to Arg 57 and one water-mediated
hydrogen bond to Arg 57 and Lys 32 (Figure 17), as opposed to the water network
formed with between the carboxylate and Arg 57 in both UCP1106 and UCP1175
structures. This direct interaction is believed to occur in all of the propargyl substituted
PLA-COOHs, explaining the increased activities of UCP1172, UCP1173, UCP1205 and
UCP1206. Conversely, the R1-methoxy substitution of UCP1163 and UCP1164 is
believed to dictate its binding location, where substitutions of the propargylic position are
not likely push the biphenyl system closer to Arg 57.
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Figure 17 Binding of UCP1191 in the active site highlighting the a) water mediated
interaction with Arg 57 and b) direct hydrogen bonding interactions.

Both UCP1106 and UCP1175 structures feature the cyclized α-anomer of NADPH in the
cofactor-binding site. The structure with DfrB:NADPH:UCP1106 shows 40% occupancy
and that with DfrB:NADPH:UCP1175 shows 100% occupancy of the tricyclic α-NADPH
anomer. DfrB:NADPH:UCP1191 contains 100% occupation of the extended β-NADPH
cofactor. This switch in NADPH identity, discussed in Section 2.5, is believed to be a
result of the binding position of the acetylene linker, dictated the various propargylic and
B-/ C-ring substitutions.

Allowing the incorporation of negatively charged functionality to the PLA scaffold and the
addition of key contacts with the enzyme afforded some of the most potent and selective
activity seen within the class of antifolates. Structural studies reveal how the incorporation
of a carboxylate moiety can mimic one of the key interactions common to classical
antifolates. Specifically, it was demonstrated that modifications to B-ring and propargylic
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substitutions allow for the optimization of inhibitor binding. Optimization within this series
of compounds resulted in the displacement of a water network and the formation a strong,
direct ionic interaction with the side chain of Arg 57. As Arg 57 is conserved in pathogenic
DHFR enzymes, specifically TMPS and TMPR S. aureus associated enzymes; it is likely
that the interactions between these PLAs with this residue will also be conserved; this
point is an important distinction that will be highlighted in Chapters 4 and 5.

2.5 Role of NADPH in PLA Binding and Activity
Crystallographic studies of propargyl-linked antifolates with S. aureus DHFR revealed an
unexpected, novel NADPH configuration. This phenomenon was first observed in a series
of wild-type and mutant crystal structures with a panel of first generation PLAs14,15.
Initially, this alternative NADPH was believed to be β-NADPH bound in a novel
conformation, however further analysis has revealed that the change is actually a
consequence of a switch in configuration at the anomeric carbon of the nicotinamide
ribose to produce the α-form. NADPH is known to exist in equilibrium between the two
anomers, with a distribution of approximately 1.5 % α- and 98.5% β-form27. The β- to αanomerization requires a reversible ring opening, ring-closing mechanism (Figure 18).
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Figure 18 The mechanism of the reversible, acid catalyzed β- to α-NADPH
anomerization followed by the irreversible tautamerization.

Upon additional scrutiny of the crystal structures and their electron density maps, it was
discovered that the α-NAPDH anomer actually exists in its cyclized, closed tautomer state
(Figure 18, 19). This additional step results in the formation of a covalent bond (Figure
18) that requires the precursory β- to α- anomerization to occur in order for the
nicotinamide and ribose alcohol to be on the same plane for reaction28,29. However,
biochemical evaluations show that tNADPH is neither an active cofactor nor an inhibitor of
DHFR, as enzymatic assays with the purified tricyclic NADPH have an IC50 of 111 +6 uM.
While the source of the tricyclic NADPH is unknown, it is believed that the protein
facilitates and stabilizes the condensed α-NADPH configuration, which is believed to be a
transition state for the transformation of tricyclic-NADPH29.
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Figure 19 Difference density (dark blue) in the structure of DfrB:NADPH:UCP1061
indicates that alpha NADPH anomer (purple) exists in the closed ring tautomer state
(magenta). Moving the ribose alcohol to fit the difference density resulted in the ring
closure, capturing the rigid NADPH tautomer.

In the structures featuring the tNADPH, the nicotinamide ring is displaced 2.5Å for amine
and 4.5Å for the carboxyl atom compared to its β-NADPH counterpart. The displaced
nicotinamide ring coordinates three water molecules between the amide and the
backbone of Phe 92, Ile 14 and Ala 7, whereas the nicotinamide amide of β-NADPH
forms direct hydrogen bonding interactions with Ala 7 (Figure 20). Additionally, the
alternative anomer displaces a water molecule coordinated between the nicotinamide
phosphate of β-NADPH and the sidechain of Asn 18, which becomes occupied by the
ribose moiety of α-NADPH stabilizing the condensed NADPH conformation. Cyclization
results in the slight displacement of a water coordinated between the ribose and side
chains of Asn 18 and Asp 120, however the displaced ribose gains a direct interaction
with Asn 18 (Figure 21).
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Figure 20 The interactions of the nicotinamide rings of both beta- and tricyclic-NADPH
with DfrB active site. The beta-NADPH (blue) forms two direct hydrogen bonding
interactions with Ala 7 and the tricyclic-NADPH (purple) coordinates three water
molecules between Ala 7, Phe 92 and Ile 14 (not shown).
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Figure 21 The interactions between a) beta-NADPH (green) and b) tricyclic-NADPH
(purple) ribose and ribose phosphate and DfrB. The waters and hydrogen bonding
interactions associated with the extended B-NADPH are shown in green and those
associated with tricyclic NADPH are shown in black. Panel C shows the superposition of
the two structures, highlighting the significant structural changes that the protein must
undergo to accommodate the two NADPH anomers.

The transformation from the extended β-NADPH to the condensed alpha and tNADPH
conformation is possible by the flexibility and plasticity of the internal NADPH phosphates.
These phosphates reorient to form a hydrogen-bonding interaction with Gln 95 backbone
instead of a 2.6Å hydrogen bond with a water networked between the sidechain of Asn 18
and an Asp 120 coordinated water of β-NADPH. This reorientation maintains a 2.6Å
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hydrogen bonding interaction with Thr 46 and Thr 96, although the latter interacts with the
phosphate through a different plane (Figure 22).

Figure 22 The interaction of the internal phosphates of beta- (green) and tricyclic(purple) NADPH, the bonding interactions are shown in green and black, respectively.
The binding interaction between the pterin ring and the protein are conserved in both
beta- and tricyclic NADPH

Biochemical (Section 2.3, Figure 11) and structural analysis indicate that both tricyclic
and beta-NADPH can form stable ternary structures with the DfrB and inhibitors,
specifically UCP1061 and UCP1062. Interestingly, a crystal structure of UCP1006, the
racemic mix of UCP1061 and UCP1062, exclusively selects beta-NADPH and its
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corresponding enantiomer, potentially indicating preference for the beta-anomer complex.
While the exact mechanism by which the alternate cofactor is recruited to the
protein:inhibitor complex is still unknown, the binding of the inhibitor, influenced by both
mutations in DfrB and the structure of the inhibitor of itself, appear to influence this
selection. For example, UCP1061 and UCP1062 differ by a single stereogenic center and
recruit 100% occupancy of the tricyclic-NADPH and beta-NADPH, respectively. In the
structure with UCP1061, where α-NADPH is primarily stabilized by van der Waals
interactions by the projection of the methyl group inhibitor into a pocket formed by Phe 92
and Thr 46. However, one of the water molecules coordinated between the NADPH and
protein forms a hydrogen bond with the Phe 92 backbone, which forms extensive
hydrophobic interactions with the acetylene linker (Figure 23).

In addition to the stereogenic steering of the biaryl system, a 1.5Å displacement of the
acetylene linker is observed, resulting from the position of the RP methyl (Figure 23) with
the inhibitor whose linker binds nearer to the NADPH biding site UCP1061), correlates to
the tricyclic NADPH. This shift in the acetylene linker was also observed with the panel of
COOH-PLA’s whose binding position was attributed to the coordination of waters, or
direct hydrogen bonding interaction with Arg 57 (Section 2.4). While it is possible that the
binding position of the acetylene linker is an artifact of the identity of the NADPH present,
the potent activity and assumed potent binding of the PLAs is assumed to be preferential
to that of NADPH.
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Figure 23 The binding of the PLAs, directed by a single stereogenic center, appears to
influence the recruitment of the NADPH anomers. The distance between the proparyglic
carbon atoms of UCP1061 (purple) and UCP1062 (green) is 1.5Å.

2.6 Conclusions
The development of a novel class of antifolates, guided by the acquisition of highresolution crystal structures, has resulted in a class of compounds with potent enzymatic
and cellular activity against S. aureus DHFR. These inhibitors, evolving from
trimethoprim, retain the 2,4-diaminopyrimidine and linked various benzyl and biaryl
system through a propargylic acetylene linker. By evaluating the aryl identities of the
distal and proximal rings on the biaryl system as well as substituents on these rings and
the propargylic methyl, we can elucidate a structure-activity relationship for scaffold
optimization.
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The first identified classes of lead PLA compounds against S. aureus featuring a distalpyridine ring were optimized from a series of TMP derivatives and hydrophobic biaryl
compounds. Not only did the pyridine compounds show an increase in cellular and
enzymatic activity, the increased solubility gained by the polar character of the pyridine
was crucial for continued lead development. B-rings and RP substitutions further
optimized the class and highlighted the important role that the propargylic methyl, the sole
chiral center of the inhibitor, plays in the activity of the PLAs, therefore a panel of
enatiomerically pure PLAs were developed and analyzed.

Biological and structural studies of these enantio-pure compounds show that the
configuration of this chiral center provides essential conformational control of the biaryl
moiety as well as increases functionality proximal to the cofactor. A noteworthy
observation is that two enantiomers, containing only a single stereogenic center, drove a
unique change in the adjacent NADPH binding site, leading to the binding of a modified,
minor component of the natural cofactor. Continued modifications to the scaffold to try
and gain ionic interaction with an active site arginine and mimic the binding of the natural
substrate resulted in the generation of inhibitors further optimized against their target. By
understanding the functionality of the stereogenic center and the importance of the
carboxylate substitution on the distal benzyl ring, compounds that contain both of these
attributes display a 32-fold increase in cellular potency over TMP as well as show good
drug-like properties such as solubility and selectivity.

Finally, crystal structures of DfrB bound to cofactor and inhibitor revealed a novel
configuration of NADPH. While the potential relationship between inhibitors and NADPH
remains convoluted, the plasticity of the active site to accommodate this novel binding
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conformation reveals a previously unknown plasticity.

Additionally, the ability of the

enzyme, inhibitor and tricyclic-NADPH to form a stable inhibitory complex with diminished
interactions between the nicotinamide ring and acetylene linker
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Chapter 3
Protein Design Algorithms Predict Viable Resistance to a Lead PLA

3.1 Computer Algorithms to Predict Drug Resistance
Mutational resistance is a common mechanism conferring resistance observed in nearly
every class of antibiotics as well as chemotherapeutics and antivirals. Being able to
predict mutations in-silico and understand the specific mechanisms in which a target can
mutate and confer resistance would allow for the development of more successful and
robust therapeutics. Advancements in computational biology have fostered the
development of algorithms capable of producing these outcomes. Minimally, a successful
algorithm would predict resistance mutations that maintain enzyme function while
reducing inhibitor affinity. However, a more powerful algorithm would also predict
mutations that maintain the fitness of the pathogen and are therefore likely to be selected
in vitro or in vivo. Predicting “fit” mutations is a significant challenge because the variables
that contribute to fitness in an organism are complex and often unknown. Additionally, a
successful algorithm would predict novel mutations that are responsive to novel
compounds. A prospective strategy such as this would be especially effective in the
discovery of therapeutics for which it is difficult to generate resistant cells in vitro.

Previous attempts to predict mutational drug resistance have been reported. One study
optimized molecular dynamics and thermodynamic integration calculations to reproduce
experimentally derived data and therefore computationally predict the effects of mutations
at two well characterized amino acids on the binding of a small molecule inhibitor to the
P38α MAP kinase1. Others, focused heavily on HIV proteases, validate combinations of
various computational methods by correlating their results to obtained in-vitro mutant or
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clinical data for approved therapeutics. As these studies are retrospective analyses, often
of known mutations that arise under pressure from known drugs, they do not address the
problem of prospectively predicting a fit mutation2-4.

3.2 Prediction of resistance mutations by K* in OSPREY
In this chapter, we report the application of the structure-based protein design algorithm,
K* in OSPREY, to identify prospective single nucleotide polymorphisms (SNP) that confer
resistance to UCP1006, Figure 1, a lead PLA. In previous work5, the structure-based K*
algorithm in the OSPREY protein design suite6,7 was used to predict double mutations in
S. aureus DHFR that confer resistance to the older generation PLA. Of the top 10
predicted mutations, all of them contained mutations at Phe 92 and the top 7 contained
mutations at Val 31, with Val31Tyr prevailing; the remaining three mutations occurred at
Ile 50. A detailed biochemical and structural analysis of the top three mutations
(V31Y/F92I, V31Y/F92V and V31Y/F92S) validated K*’s ability to accurately the effect of
mutations on enzyme fitness and inhibition.

Bacterial DHFR, specifically S. aureus, is an ideal model system for these predictions as
the development of a single amino acid mutation results in trimethoprim resistance;
higher levels of resistance are conferred by the accumulation of a second mutation8. As
we continue to develop PLAs that overcome the molecular mechanisms of resistance to
TMP9, it would be useful to predict mutations that may arise for this new class of
antifolates. Using ratios of positive design scores that predict binding of the substrate,
dihydrofolate, and negative design scores that predict binding of the inhibitor,
OSPREY/K* identified catalytically competent resistance mutations6,7.
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The protein design algorithm, K* in OSPREY6, was used to identify mutations
characterized by single nucleotide polymorphisms (SNPs) that maintain binding to the
substrate, dihydrofolate, while conferring resistance to the UCP1006 (Figure 1). Nine
active site residues (Leu 5, Val 6, Leu 20, Leu 28, Val 31, Thr 46, Ile 50, Leu 54 and Phe
92) were allowed to either maintain their wild type identity or to mutate to a restricted
group of residues that involve only a single nucleotide polymorphism (Table 1).

K* searches were performed on both the substrate (DHFR:NADPH:dihydrofolate) and
inhibitor (DHFR:NADPH:UCP1006) ternary complexes. K* scores approximate the
binding affinity (Ka) and are computed as a ratio of Boltzmann-weighted partition functions
for rotamer-based conformational ensembles of the bound protein:inhibitor complex, free
protein and free ligand. Since higher K* scores
NH 2

predict greater affinity, the ideal mutation would
N

have a high score for DHF and a low or zero
score for UCP1006. The wild-type sequence was
ranked 18th with a design ratio of 1.95 x 106

OCH3

H 2N

N

N
Figure 1 Structure of UCP1006

(Table 1). Mutants that had both (I) higher
ranking than the wild-type and (II) a good predicted binding affinity to DHF (i.e., positive
design score) were considered as resistant mutants. Four mutations (V31L, V31I, L5I,
L5V) exhibiting high ratios for the scores representing positive (binding to DHF) and
negative design (binding to inhibitor) are shown in Table 2.
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Table 1 K* Rankings by Positive/Negative Design Ratio
Single
K* Rank

Nucleotide
Mutation

Substrate Positive

Negative design

Ratio: positive /

design K* Score

K* Score

negative design

1

V31L

2.16E+41

3.04E+19

7.11E+21

2

V31I

4.87E+36

8.18E+14

5.95E+21

3

L5I

6.06E+39

3.54E+24

1.71E+15

4

L5V

4.01E+44

3.44E+30

1.16E+14

5

L54R

6.31E+43

1.60E+30

3.94E+13

6

L20F

6.06E+20

1.75E+07

3.46E+13

7

V31D

1.54E+41

5.65E+32

2.72E+08

8

L5Q

2.84E+44

1.20E+36

2.36E+08

9

V31A

7.32E+40

7.86E+33

9.31E+06

10

V6G

3.92E+42

4.27E+35

9.18E+06

11

I50L

5.18E+38

5.69E+31

9.10E+06

12

F92S

2.09E+43

2.52E+36

8.32E+06

13

L54Q

2.62E+42

3.21E+35

8.14E+06

14

V31G

2.64E+40

3.38E+33

7.80E+06

15

T46A

2.88E+42

5.27E+35

5.46E+06

16

V61

1.10E+43

4.01E+36

2.75E+06

17

L28M

3.27E+42

1.58E+36

2.07E+06

18

WT

7.16E+42

3.66E+36

1.96E+06

19

T46S

4.93E+42

3.46E+36

1.42E+06

20

L28F

2.25E+42

1.73E+36

1.30E+06

21

L28W

1.29E+43

1.01E+37

1.28E+06

22

L20S

3.57E+41

2.95E+35

1.21E+06

23

L20I

3.04E+42

2.94E+35

1.03E+06

24

L20V

7.43E+41

7.40E+35

1.01E+06

25

V6A

4.71E+42

6.07E+36

7.76E+05

26

L54V

1.46E+41

2.68E+35

5.44E+05

27

L28S

1.34E+41

3.74E+35

3.59E+05
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28

V6D

1.18E+43

6.05E+37

1.95E+05

29

V6L

7.26E+42

6.47E+37

1.12E+05

30

F92V

8.18E+40

2.80E+36

2.29E+04

31

I50V

2.49E+42

1.74E+38

1.43E+04

32

L28V

3.19E+39

2.37E+35

1.35E+04

33

F92I

8.91E+40

8.48E+36

1.05E+04

34

F92C

1.02E+40

5.37E+36

1.90E+03

35

I50S

3.07E+41

2.37E+38

1.30E+03

36

I50T

1.11E+42

9.85E+38

1.13E+03

37

I50N

6.81E+41

1.53E+39

4.46E+02

38

I50M

1.00E+40

7.50E+37

1.33E+02

39

F92L

4.02E+37

4.20E+36

9.59E+00

40

L5R

4.21E+34

4.27E+35

9.88E-02

41

T46I

5.05E+36

2.25E+42

2.25E-06

42

V6F

0.00E+00

2.94E+36

0.00E+00

43

V31F

0.00E+00

8.69E-11

0.00E+00

44

T46R

0.00E+00

0.00E+00

0.00E+00

45

T56K

0.00E+00

1.14E+14

0.00E+00

46

F92Y

0.00E+00

3.10E+32

0.00E+00

47

I50F

0.00E+00

3.37E+35

0.00E+00

3.3 Biochemical and Structural Evaluation of K* Predicted Mutants
To validate the positive and negative design results from K*, site-directed
mutagenesis was used to create the top four ranked mutant DHFR enzymes: Sa(V31L),
Sa(V31I), Sa(L5I), and Sa(L5V). Michaelis-Menten kinetics (Table 2) reveal that the
enzymes maintain their catalytically competency with only minor losses in kcat/KM. The
activity of the mutant enzymes validates the success of the positive design component of
the computational search, meanwhile drastically decreased activity of the inhibitor against
the mutant enzyme validates the negative design component. Resistance, measured by
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loss in Ki, ranged from 2-fold to 58-fold, with the top-ranked mutants (V31L and V31I)
conferring the greatest level of resistance. In fact, K* accurately ranked the mutations as
their experimental ratio of inhibition constants correlates with their K* design ratio.

Table 2 Characterization of wild-type and mutant enzymes
Fold Lossb
Enzyme

K* Ratio Rank

K* design ratio

kcat/KM

(Kimut/Kiwt)
UCP1006

Sa (wt)

18

1.96 E+06

6.1 ± 0.3

n/a

Sa (V31L)

1

7.11 E+21

1.60 ± 0.06

58

Sa (V31I)

2

5.95 E+21

1.74 ± 0.07

36

Sa (L5I)

3

1.71 E+15

2.24 ± 0.1

4.4

Sa (L5V)

4

1.16 E+14

1.8 ± 0.1

1.9

The lowest energy conformations of the top-ranked mutations, SaV31L and SaV31I, were
compared to the crystal structure of wild-type SaDHFR:NADPH:UCP1006 to understand
the basis of the resistance prediction9. Carbons Cδ1 and Cδ2 in Leu 31 are predicted to
displace Phe 92, most likely to avoid steric hindrance with the phenyl side chain (Figures
2 and 3). In addition, these carbons are observed to sterically interfere with the pyrimidine
ring, displacing it from its corresponding position in the wild-type structure. Both of these
steric interactions are expected to significantly weaken inhibitor binding.
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Figure 2 Comparison of the structures of wild-type SaDHFR bound to NADPH and
UCP1006 (PDB ID: 3SGY, blue) with the K*-predicted lowest-energy structure of
SaDHFR (V31L) (yellow). All residues allowed to be flexible and to mutate during the K*
prediction are shown in yellow stick form. The cofactor, NADPH, is shown in green.

Figure 3 Computationally-predicted effect of the V31L mutation on inhibitor binding. A)
the wild-type S. aureus DHFR:inhibitor complex (shown in blue) and B) the
computationally predicted model of the mutant V31L in complex with the inhibitor (in
which the mutant is shown in magenta and the complex is shown in blue). In addition to
V31 and the inhibitor, F92 is also shown in a stick model, while the remainder of the
protein is shown in ribbon form.
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3.4 Selection of UCP1006R Mutants
3.4a Microbiological Evaluation of Generated Mutants
In order to show the application of these predictions to a living pathogen, UCP1006R
MRSA strains were generated and selected by the bacteria under pressure from
UCP1006 and probed for mutations in the endogenous DHFR (dfrB). A first round of
selection revealed a single F98Y mutation. F98Y (a TTT to TAT transversion mutation), a
mutation that has been clinically identified as a mechanism that S. aureus DHFR confers
resistance to TMP, has a resistance frequency of 1.21 x 10-12. The F98Y strain was then
exposed to a second round of mutant selection experiments. Five of the generated nine
colonies of surviving bacteria yielded the computationally predicted V31L mutation (a GTT
to CTT transversion mutation). An overall frequency of 7.56 x 10-24 reflects the step-wise
mechanisms in which the mutations developed. One of the nine colonies yielded V31G
(14th in the ranked list, with a 10-fold increase in the K* ratio over the wildtype) and the
remaining three colonies possessed only F98Y. Both the single F98Y and double
V31L/F98Y mutant strains were characterized to evaluate antimicrobial susceptibility and
relative fitness. Trimethoprim, whose resistance profile includes the F98Y mutation, was
included as a reference (Table 3). A comprehensive evaluation of all mutant strains
generated in these and additional selection experiments are characterized in Chapter 4.

Table 3 Characterization of Strain Susceptibility and Fitness
MIC UCP1006

MIC TMP (µg/mL)

Relative

Doubling Time

(µg/mL)(fold loss)

(fold loss)

Fitness

(min)

Wild-type

0.0781

0.3123

1

22.5

F98Y

2.5 (32)

10 (32)

0.98

23.2

V31L, F98Y

20 (256)

40 (128)

0.86

25.4

Strain
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UCP1006 and TMP have MIC values of 2.5 µg/mL and 10 µg/mL for the F98Y strain,
respectively, representing a 32-fold loss when compared with the wild-type ATCC 43300
strain. The addition of the V31L mutation confers an additional 8-fold loss for UCP1006
and 4-fold loss for TMP, resulting in total 256- and 128-fold losses, respectively. As
observed previously, the Sa(F98Y) DHFR mutation does not reduce the fitness of the
strain10,11. The presence of the V31L/F98Y mutation reported here results in minimal (14
%) loss of fitness, as measured by a pair-wise fitness assay. Log-phase cell growth was
minimally affected by the presence of the single F98Y or double V31L/F98Y mutation with
doubling times at 22.5 minutes for the wild-type strain and 23.2 and 25.4 minutes for the
mutants, respectively.

3.4b Biochemical Evaluation of Generated Mutants
In order to understand why the V31L mutation arises only in the background of the F98Y
mutation, we examined detailed inhibition and kinetic data for the enzymes. Here, we also
included the F98Y mutation and data for trimethoprim as a comparator. The Sa(F98Y)
mutation has more pronounced effects on trimethoprim, resulting in 38- and 5-fold losses
in Ki against trimethoprim and UCP1006, respectively. However, the Sa(V31L) mutation
affects UCP1006 more significantly, resulting in 15- and 60-fold losses in Ki against
trimethoprim and UCP1006 (Table 4). The Sa(V31L,F98Y) double mutant clearly confers
much greater resistance with a 148-fold loss in Ki for trimethoprim and an 189-fold loss in
Ki for UCP1006.

Michaelis-Menten constants, determined for each of the enzymes (Table 4), reveals a
compensatory relationship between the mutations. The KM value for DHF is reduced from
the wild-type value (17.5 μM) by 2-fold for Sa(F98Y)DHFR to 8.4 μM while the same
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value for Sa(V31L) DHFR is increased by 2.4-fold to 42.9 μM. In combination, the
Sa(V31L/F98Y) DHFR restores the KM for DHF to 4.1 μM. Interestingly, the KM value for
NADPH for Sa(F98Y) increases to 56.8 μM from the wild-type value of 32.6 μM and the
KM value for NADPH in Sa(V31L) decreases to 15.6 μM. The double mutant maintains the
decreased KM of Sa(V31L) and has an overall lower KM relative to wild-type at 22.3 μM.
Taken together, the data show that while F98Y and V31L negatively affect NADPH and
DHF, respectively, the two mutations in combination restore the K M values to wild-type
levels. Additionally, the kcat/KM value for the double mutant is increased to 10.9 μM-1.

Table 4: Characterization of MRSA Generated Mutant Enzymes
TMP

UCP1006

DHF

NADPH

DHFR

Ki, nM

Ki, nM

KM, μM

KM, μM

WT

3.5 ± 0.5

2.8 ± 0.2

17.5 ± 2

F98Y

131 ± 4

13 ± 1

V31L

54 ± 2

V31L, F98Y

520 ± 30

kcat

kcat/KM

32.6 ± 4

106.9 ± 2

6.1 ± 0.3

8.4 ± 0.7

56.8 ± 5

44.7 ± 0.4

5.33 ± 0.08

170 ± 20

42.9 ± 3

15.6 ± 3

68.8 ± 2

1.60 ± 0.06

530 ± 30

4.1 ± 0.8

22.3 ± 2

44.8 ± 2

10.9 ± 0.8

3.5 Structural Analysis of Sa (V31L, F98Y) DHFR
The data in Tables 2 and 4 indicate that the mutations have a direct influence on
substrate and cofactor binding as well as inhibitor potency. In order to understand the
structural effects of the mutations, we determined a crystal structure of the double mutant
enzyme. Crystals of Sa (V31L, F98Y) DHFR produced diffraction amplitudes to 2.1 Å
when co-crystallized with NADPH and a propargyl-linked antifolate that is structurally
similar to UCP1006. The structure was solved using Fourier methods based on the model
of the single mutant Sa(F98Y) bound to NADPH and a propargyl-linked antifolate (PDB

75

ID:3F0U)12.

The Sa(V31L, F98Y) structure features the standard extended form of

NADPH but lacks the PLA present during co-crystallization.

Comparisons of the Sa (V31L, F98Y) structure with the structure of wild-type enzyme
bound to UCP1006 reveal a structural basis of resistance indicated by significant
conformational changes induced by the presence of the two mutations. The most
significant amino acid reorientations are observed between Phe 92, Val 31 and the
binding site of the diaminopyrimidine moiety of UCP1006. The major change centers on
Leu 31 that projects 2.0 Å further into the active site than the wild-type Val 31 residue,
resulting in a corresponding 2.3 Å shift in Phe 92 into the active site and 1.4 Å shift of the
backbone carbonyl (Figure 2a). This new Phe 92 orientation restricts the side chain from
adopting the position needed for ligand binding and disrupts stabilizing hydrophobic
interactions with the acetylene linker. The shift of the Phe 92 carbonyl also results in the
loss of a hydrogen bond to the 4-amino group of the pyrimidine. Additionally, Leu 31 is
2.2 Å from the 6-ethyl substituent of the diaminopyrimidine, indicating potential repulsive
steric interactions.
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Figure 4 Crystal structures of the wild-type and mutant enzymes show conformational
changes at Phe 92 and His 30. a) Superposition of the structures of
Sa(wt):NADPH:UCP1006 from PDB ID: 3SGY (blue) with Sa(V31L,F98Y):NADPH
(magenta)

Figure 4 Crystal structures of the wild-type and mutant enzymes show conformational
changes at Phe 92 and His 30. b) Superposition of the structures of
Sa(wt):NADPH:UCP1006 from PDB ID 3SGY (blue) with Sa(F98Y):NADPH (yellow) and
Sa(V31L/F98Y):NADPH (magenta).
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Furthermore, the B-helix, adjacent to the active site and possessing critical amino acids
for ligand binding, shifts 0.4 Å away from the active site. Distances between the ligand
and amino acids Asn 25, Asp 27, His 30 and Leu 34 are increased by 0.4 Å,
concomitantly reducing hydrogen bonding and van der Waals interactions essential for
stability and ligand binding. Moreover, the shift in the B-helix results in a 1.1 Å shift in the
imidazole ring of His 30. The shifted His 30 side chain extends the binding site, allowing
for a glycerol molecule to displace a water molecule that typically provides stabilizing
hydrogen bonds between the pyrimidine amino group of UCP1006 and the His 30
imidazole (Figure 5).

A similar disruption of the water network has been previously

shown in a crystal structure of the clinically observed resistance mutant Sa (H30N, F98Y)
with NADPH and a propargyl-linked antifolate13. In combination, the observations for Phe
92, Leu 31 and the B-helix explain the lower affinity of UCP1006 for the mutant enzyme.

The Sa(V31L, F98Y) enzyme maintains catalytic competency. Comparisons of the
Sa(V31L/F98Y) structure with wild-type Sa/NADPH/DHF (PDB ID: 3FRD)14 indicates that
a shift in the Phe 92 peptide carbonyl would have little or no effect on DHF binding or
turnover since there are no direct interactions between the two groups. Any minor steric
interactions between Phe 92 and the pterin ring of DHF may be compensated by the
additional interactions in the glutamate tail that remain undisturbed.

In order to verify which structural effects result from the presence of the mutations and
which result from enzyme lacking a bound ligand, we determined the structure of
Sa(F98Y)DHFR bound only to NADPH. Comparisons of the structures of binary
Sa(F98Y):NADPH, Sa(F98Y/V31L):NADPH and ternary Sa:NADPH:UCP1006 indicate
that the reorientations of Phe 92 and His 30 are due to the presence of the mutations.
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Like the Sa(F98Y/V31L):NADPH structure, the Sa(F98Y):NADPH structure features the
same 0.4 Å shift of the B-helix away from the active site. However, the conformation of
Phe 92 in the Sa(F98Y/V31L) structure appears to be influenced by the V31L mutation
as the conformation of this residue in the Sa(F98Y) structure is approximately 0.5 Å
closer to that observed in the ternary structure. Similarly, the V31L mutation influences
the conformation of His 30 as a comparison of the Sa(F98Y):NADPH and ternary
(Sa:NADPH:UCP1006) structures shows that the His 30 conformation is the same (Figure
2b).

Figure 5 A molecule of glycerol is observed to bind in the active site of the structure of
Sa(F98Y/V31L):NADPH. The Sa(F98Y/V31L) structure is shown in magenta, the 3SGY
structure (Sa(wt):NADPH:1) structure is shown in blue for reference. The molecule of
glycerol replaces the 2-amino group and a water molecule found in the wild-type
structure.
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Comparisons of the crystal structure of Sa(F98Y/V31L):NADPH with the lowest energy
predicted structure of the K*-predicted single V31L mutant (Figure 1) shows a
conservation of the effect of the V31L mutation on Phe 92. The predicted structure also
indicates a steric interaction between Leu 31 and the C6-ethyl substituent of the
pyrimidine ring of UCP1006, which compliments the crystallographic results. Incidentally,
when K* was previously used to predict resistance mutations with another propargyllinked antifolate that maintains the same atoms as UCP1006 other than possessing a
methyl instead of an ethyl group at the C6 position of the pyrimidine ring, the Val 31
mutants ranked lower than the Leu 5 mutations. These results further validate that the
steric interaction between Leu 31 and the ethyl group specifically contribute to resistance.

3.6 Conclusions
In summary, the K* algorithm in OSPREY was successfully used to predict unique single
amino acid mutations in the active site of S. aureus DHFR that confer resistance to
UCP1006. Four of the predicted mutant enzymes were created and shown to be
catalytically competent and resistant to UCP1006, with the top-ranked mutant having a
58-fold reduction in inhibitor potency. Excitingly, the computational predictions were
shown to not only be biochemically validated, but also selected in the bacteria under
antibiotic pressure as the top-ranked mutation, V31L, was selected in the background of
an F98Y mutation, which has been clinically observed. Exploration of the enzymatic
fitness of this novel double mutant revealed a compensatory relationship between the
single F98Y and V31L mutations that results in a doubly mutated enzyme with fitness
comparable to the wild-type enzyme. Consideration of the cellular fitness revealed that
the double mutant strain only suffered a slight loss in fitness over both the progenitor
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strain and the previously characterized F98Y strain. Crystal structures of the double
mutant enzyme revealed the structural basis of compound resistance.

The mutation V31L emerged as the top-ranked SNP that maintained dihydrofolate binding
while conferring inhibitor resistance by perturbing Phe 92 and sterically interfering with
the C6-ethyl group of the pyrimidine ring. Interestingly, there is a strong correlation
between the current results and those obtained in the first application of K* to identify
double mutants of SaDHFR that confer resistance. In the previous study5, the seven topranked mutations were variants of Val 31 and Phe 92; a crystal structure of the
V31Y/F92I mutant enzyme shows that the F92I mutation reduces van der Waals
interactions and the V31Y mutation introduces destabilizing steric bulk.

Overall, it is

striking that the same structural effect is selected with both applications of K* whether it is
applied to identify double or SNP mutations.

Having validated the mutational prediction capabilities of K*/OSPREY via bacterial
selection of the predicted mutants, the algorithm could potentially be applied to many
different research areas. Specifically, the computational prediction of drug-resistance
mutations could be valuable in cases where it is more difficult to raise mutant strains or
cell lines in vitro, such as with viruses or cancer cell lines. Overall, the extension of the
computational prediction of drug resistance to observations of biologically relevant
mutants provides new opportunities in drug discovery, especially for those targets that are
most affected by mutational resistance.
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Chapter 4
Understanding and Overcoming Mutational Resistance to Trimethoprim with Charged
Antifolates

4.1 Understanding Mutational Resistance in S. aureus
The accumulation of amino acid mutations in the active site of the drug target is a
common mechanism of antibiotic resistance implicated in the loss of clinical efficacy to
antifolates, including TMP1 and SMX2, as well as fluoroquinolones3. Sulfamethoxazole
resistance is conferred by the accumulation of up to thirteen mutations in the
dihydropteroate synthase (DHPS) whereas a variety of mutations across the DNA gyrase
A (gyrA) and topoisomerase A and B (grlA and grlB) results in resistance to
fluoroquinolones2,3. The first description of mutations in the endogenous DHFR (dfrB)
reported four sets of mutations that determined clinical TMP resistance across Europe,
the UK and South America4. The group of mutations includes F98Y, the combinations of
F98Y with H30N or H149R and a L20V, N59I and F98Y triple mutant. The single F98Y
mutation resulted in a 64-fold loss in cellular potency whereas the double and triple
mutants resulted in a 254-fold loss of activity. Structural studies indicate that the presence
of the Tyr 98 disrupts the Phe 92 binding resulting in the loss of a hydrogen bonding
interaction between the Phe 92 backbone carbonyl and the 4-amino group of the
diaminopyrimidine. The formation of an interior hydrogen bond between the Tyr 98 phenol
and the Leu5 backbone carbonyl, further reducing the hydrogen bonding interactions
between TMP and the active site, was observed4.

Additional studies indicate that the presence of the F98Y mutation disrupts cofactor
binding and diminishes the crucial synergy between TMP and NADPH, which in turn
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confers resistance5. More in-depth crystallographic studies looking to overcome F98Y
mutation with early generation of PLAs indicates that an alternative NADPH conformation
correlates with decreased activity against this enzyme6. While the exact mechanism by
which Tyr 98 confers resistance remains convoluted, its impact on clinical antifolate
resistance remains of the utmost importance. Furthermore, comprehensive biochemical
and structural analysis of the clinically isolated TMPR double mutant, Sa (H30N, F98Y)
DHFR indicates that the double mutant doesn’t only confer high levels of TMP resistance,
but that the accumulation of mutations does not compromise enzymatic efficiency. Crystal
structures of this enzyme bound to a first generation PLA showed that the loss of a water
mediated hydrogen bond between His30 and Thr111 is responsible for the loss of TMP
efficacy7. Compounding this observation with previously understood effects of the Phe98
mutation on NADPH and inhibitor binding allows for a complete understanding of
mutational resistance and allows for the development of more robust inhibitors.

In vitro generation of resistance is achieved by extended exposure of large
concentrations (1011 to 1012 CFU/mL) of bacterial culture to high concentrations (6x MIC)
of inhibitor. Upon exposure to inhibitor, the resistant bacteria are revealed and can grow
unharmed under the antibiotic pressure. It is unclear whether these revealed mutant
strains are generated directly in response to antibiotic pressure from a stress response or
if these resistant bacteria pre-exist in small quantities and are revealed upon the death of
the susceptible population. The first report of the prospective analysis of mutational
resistance to early generation PLAs in S. aureus yielded the selection of F98Y, F98I and
H30N single mutants at a very low (10-10) mutational frequency. It was also observed that
the series of PLAs exhibited superior potency over TMP against these enzymes and
showed lower mutation prevention concentrations (MPCs). This indicates that the class of
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antifolates can compensate for the resistance effect of the mutations, are potentially less
susceptible to mutational resistance and are promising candidates to overcome clinical
resistances.

4.2 Generation and characterization of UCP1006R MRSA strains
To further characterize the resistance profile of the propargyl-linked antifolates, strains
containing point mutations in the dfrB, generated by extended UCP1006 exposure, were
selected and analyzed by microbiological, biochemical and structural mechanisms. For
single-step mutant selection, the ATCC quality control strain 43300 was subjected to
UCP1006 at 6x MIC yielded three clinically observed mutations: F98Y, H30N and H149R
as well as three novel mutations: F151S, F151C and D142Y. A second round of
resistance selection using UCP1006 and progenitor strains possessing F98Y or H149R
yielded a series of both novel and clinically relevant double mutants (Table 1). As strains
containing H30N/F98Y and F98Y/H149R mutants have been isolated clinically after
exposure to TMP1, we chose to fully characterize the fitness of these mutant enzymes
and bacteria, including their single mutant (F98Y, H30N, H149R) counterparts (Table 1)
at a biochemical, structural and cellular level.
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Table 1 Mutant Strain Selection using UCP1006
Progenitor

Single Nucleotide

Seq.

Overall

Doubling

Strain

Polymorphism

Frequency (%)

Freq

time (min)

F98Y

WT

TTT to TAT

2/19 (10.5)

3.11x10-11

34.53

H149R

WT

CAT to CGT

7/19 (36)

1.07x10-10

38.34

H30N

WT

CAT to AAT

3/19 (15.8)

4.68x10-11

36.62

F151S

WT

TTT to TCT

3/19 (15.8)

4.68x10-11

ND

F151C

WT

TTT to TGT

2/19 (10.5)

3.11x10-11

ND

D142Y

WT

CAT to TAT

1/19 (5.3)

1.57x10-11

ND

H30N/V70L

WT

GTA to TTA

1/19 (5.3)

1.57x10-11

ND

F98Y, H149R

H149R

TAT to TTT

1/1 (100)

1.23x10-11

30.89

H30N, F98Y

F98Y

CAT to CGT

2/16 (12.5)

8.20x10-12

35.06

F98Y, F151S

F98Y

TTT to TCT

1/16 (6.25)

4.10x10-12

ND

1/16 (6.25)

4.10x10

-12

ND

-11

ND

Mutant

F98Y, F151C

F98Y

TTT to TGT

V31G, F98Y

F98Y

GTT to GGT

6/16 (37.5)

2.46x10

V31L, F98Y

F98Y

GTT to CTT

5/16 (31.3)

2.05x10-11

25.4

1/16 (6.25)

4.10x10-12

ND

V31G, F98Y,
V112D

F98Y

(V31G) GTT to GGT
(V112D) GTT to GAT

Overall mutation frequencies for each strain exposed to UCP1006 were calculated based
on the inoculum and average number of colonies appearing on the 6x MIC experimental
plates. Resistance to UCP1006 with S. aureus is generated at a very low frequency of
2.96 x 10-10. Overall mutation frequencies are even lower to progenitor strains possessing
F98Y and H149R, with rates of 6.56 x 10-11 and 3.75 x 10-11, respectively. Specific
mutational frequencies were then calculated based on the number of sequenced colonies
with a particular mutation. If the generation of double mutants occurs in a step-wise
fashion, the combined frequency of resistance could be as low as 10-21. Evaluation of
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bacterial fitness, measured by doubling time, shows that the majority of the mutant strains
exhibit only minor losses in growth time (1.08-1.2 x doubling time of wild-type), with the
exception of Sa(F98Y/H149R), which preserved or slightly improved doubling time (Table
1). Overall, these studies show that the accumulation of the mutations retains cellular
fitness of the strains.

4.3 Generation and Evaluation of UCP1006R Enzymes
The recombinant mutant DHFR enzymes were created by site-directed mutagenesis of
the wild-type enzyme and purified using affinity chromatography. Michaelis-Menten
kinetics were measured for each enzyme using 12.5-100 µM NADPH and 12.5-100 µM
DHF (Table 2)9. Overall, the enzymes, with the exception of Sa(H149R), have kcat/KM
values within approximately 2-fold of the wild-type value. Sa(H149R) has a significantly
reduced kcat/KM value (6-fold reduction), which is a consequence of higher KM values for
both DHF and NADPH. Interestingly, the double mutant Sa(F98Y/H149R) compensates
for the low efficiency of the single Sa(H149R) mutant as the Sa(F98Y/H149R) enzyme
restores the KM value for DHF and NADPH to nearly wild-type values. Similarly, the single
H30N mutation suffers a significant decrease in NADPH KM (31.21 to 79.89 µM); this KM
value is restored to a value near wild-type in the double Sa(H30N/F98Y) mutant. This
compensatory relationship was observed in the analysis of F98Y, V31L enzymes
generated after the K* prediction, however here, the single mutants are also fit9.
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Table 2 Mutant Enzyme Characterization
KM (DHF)
(μM)

Vmax (DHF)

KM (NADPH)

kcat DHF

kcat/KM

(μM)

(s-1)

DHF

WT

17.5

62.93

31.21

41.13

2.4

F98Y

8.38

68.38

57.08

44.76

5.3

H30N

24.49

45.76

79.89

29.91

1.2

H30N, F98Y

11.24

39.98

51.17

26.1

2.3

H149R

63.54

42.44

303.4

27.74

0.4

F98Y, H149R

5.24

44.98

45.08

29.40

5.6

4.4 Propargyl-linked Antifolates Overcome Mutational Resistance
Understanding mutational resistance to UCP1006 is critical for guiding the development
of a newer generation of robust PLAs that overcome the effects of the point mutations. By
examining previously identified structure-activity relationships6,

8, 10

and testing several

compounds likely to inhibit the single mutant enzymes, we initially identified a series of
pyridine lead compounds, UCP1006, UCP1038, UCP1039 and UCP1040, with potent
MICs against the single mutant strains and enzymes. The incorporation of the knowledge
that enantio-specific methyl substitutions at the propargyl position can steer the biaryl
system and result in a further optimized interaction with the enzyme led to the evaluation
of UCP1062, UCP1063 and UCP109912. These enatio-pure PLAs further increased the
activity against single mutant strains and enzymes and showed the first hints of activity
against the double mutant strains.

Finally, incorporation of the carboxylate C-ring

substitution on ring to the initial set of promising compounds lead to a series of
compounds potent enzymatic and cellular activity across all single and double mutant
species11 (Figure 1, Tables 3 and 4).
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All of the compounds exhibit good potency (Ki values less than 16 nM, against the single
mutant enzymes Sa (F98Y) and Sa(H30N) with only minor losses relative to wild-type
(Table 4). UCP1038 lost the greatest affinity for the Sa(H30N) enzyme with a 12.6-fold
loss. Activity against the single mutant Sa(H149R) was more compromised, where TMP
loses activity against the Sa(H149R) mutant by 69-fold. The PLAs possess a range of
affinity for this enzyme, ranging from UCP1173 with a Ki value of 153 nM to UCP1038
with a Ki value of 1362 nM. UCP1039 with unconstrained 3’ and 4’ methoxy groups
maintained reasonable affinity with a Ki of119 nM when compared to compound
UCP1038, showing that flexibility, in addition to the propargylic subsitutions, may be
critical for affinity to the mutant enzymes. In general, the dioxalane compounds
(UCP1038 and UCP1099) as well as compounds UCP1040, 1062 and 1063 lose
significant affinity for the Sa (F98Y, H30N) double mutant enzyme (180 to 300-fold loss),
TMP losses 130-fold loss of activity against this enzyme. Inhibition of Sa (F98Y, H149R)
remains a struggle for the pyridine substituted PLA series.

The PLA-COOH class of compounds was designed to form ionic interactions with a
conserved arginine to provide compensatory interactions in these mutant enzymes.
These COOH substituted compounds, with the exception of UCP1106, show much
greater affinity for the double mutant Sa (F98Y, H30N) enzyme with Ki values ranging
from 19-45 nM. With Ki values of 107-2059 nM against the double mutant Sa (F98Y,
H149R) enzyme pyridine compounds as well as UCP1106 and TMP maintain challenge.
However, UCP1172 and UCP1173 show significant inhibition for this enzyme, with Ki
values of 69 and 55 nM, respectively. Again, it appears that the presence of the ionized
carboxylates may provide critical additional interactions to compensate for reduced
contacts elsewhere in the complex.
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Figure 1. Structure of Trimethoprim and PLAs
Table 3 Ki (nM) of PLAs against WT and mutant enzymes
Compound

Sa(WT)

Sa(F98Y)

Sa(H30N)

Sa(H149R)

Sa(H30N,

Sa(F98Y,

F98Y)

H149R)

TMP

3.4+0.3

14.68+0.08

6.9+0.2

240+10

595+5

1729+40

UCP1006

2.8+0.3

13.1+0.7

12.9+1

681+27

191+10

2059+200

UCP1038

2.5+0.1

3.0+0.4

33.2+1

1363+38

485+40

779+25

UCP1039

2.1+0.1

12.1+0.6

4.5+0.4

119+7

449+40

107+9

UCP1040

4.51+0.09

19.7+1

5.9+0.9

1563+34

820+80

878+30

UCP1062

2.6+0.3

8.6+0.4

16.7+0.6

1154+19

801+51

894+84

UCP1063

1.6+0.1

16.7+1

16.5+1

269+20

417+30

422+14

UCP1099

5.2+0.3

13.6+0.8

8.9+0.6

174+4

345+10

289+20

UCP1106

4.8+0.1

11.7+0.5

3.9+0.4

130+3

158+4

142+2

UCP1164

5.5+0.1

11.8+0.7

3.8+0.6

862+39

36+3

295+9

UCP1175

1.64+0.09

11.3+0.7

3.36+0.06

323+23

45+3

184+5

UCP1172

1.3+0.1

7.9+0.2

3.5+0.6

111+7

19+1

69+2

UCP1173

2.1+0.1

5.57+0.08

3.3+0.2

153+11

16.6+0.3

55+1
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The compounds were also tested for inhibition of the growth of wild-type and mutant
(Sa(F98Y), Sa(H30N), Sa(H149R), Sa(H30N, F98Y) and Sa(F98Y/H149R)) strains of S.
aureus (Table 3). The antibacterial activity of TMP was clearly crippled by even the single
mutations and reached a 50-100 µg/mL MIC value against the double mutant strains. The
pyridine PLAs as well as UCP1106 and UCP1164 were more potent against the wild-type
strain than TMP and many were more potent against the single mutants (MIC values
between 0.078 and 5 µg/mL). However, these compounds also suffered significant losses
against the strains with double mutations in DHFR. PLAs UCP1172, 1173 and 1175 have
superior activity against the wild-type strain as well as strains with both single and double
mutants. Notably, the MIC value for UCP1173 against either of the double mutant strains
is only 4-fold higher than the MIC value of TMP for wild-type S. aureus. On-target activity
of the PLAs was verified end-product rescue MICs, in which the folic acid cycle is
bypassed by the increased concentration thymidine concentration in the growth media
(Thy+)11,12. All compounds, with the exception of UCP1038, UCP1062 UCP1063 and
UCP1099 have Thy+ MICs of >40 µg/mL, where UCP1038, UCP1062 and UCP1063 have
Thy+ MICs of 5 µg/mL and UCP1099 had an MIC of 10 µg/mL. These MIC values rise by
64x – 4081x, validating that the compounds inhibit DHFR.
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Table 4 Minimum Inhibitory Concentrations (µg/mL)
Compound

ATCC
43300

Sa(F98Y)

Sa(H30N)

Sa(H149R)

Sa(H30N,

Sa(F98Y,

F98Y)

H149R)

TMP

0.3125

10

2.5

2.5

50

100

UCP1006

0.0781

2.5

2.5

2.5

20

80

UCP1038

0.0781

1.25

5

5

40

40

UCP1039

0.0195

0.625

0.625

0.625

20

40

UCP1040

0.625

2.5

2.5

2.5

20

40

UCP1062

0.0391

0.625

0.625

0.625

40

20

UCP1063

0.0195

1.25

0.625

1.25

10

20

UCP1099

0.0195

1.25

2.5

2.5

20

20

UCP1106

0.0195

0.1563

0.1563

0.1564

6.25

>50

UCP1164

0.0391

0.1563

0.1563

0.0781

>40

>40

UCP1175

0.0195

0.1563

0.1563

0. 1563

5

10

UCP1172

0.0098

0.0781

0.0781

0.0391

1.25

2.5

UCP1173

0.0098

0.0781

0.0781

0.0781

1.25

1.25

4.5 Structural Analysis of Mutant Enzymes and UCP1106
A series of crystal structures with the wild-type and mutant enzymes elucidates the
structural changes caused by the selected mutations. Mutants Sa (F98Y), Sa (H30N) and
Sa (H30N, F98Y) DHFR were co-crystallized with NADPH and UCP1106; the structure of
the wild type Sa DHFR complex with NADPH and UCP1106 has been previously
described (PDB: 5HF0; Figure 1)11.

The structures of the wild-type and Sa (H30N)

enzymes feature mixed occupancy of tricyclic- and β-NADPH in the cofactor binding site
(Figure 2), similar to previous observations6, 10.

93

Figure 2 View of wild-type SaDHFR (purple) bound to β-NADPH (salmon), α-NADPH
(yellow) and UCP1106 (green).

The structural basis of antifolate resistance in these F98Y mutant enzymes appears to
involve the loss of a critical hydrogen bond between the carbonyl backbone of Phe 92
and the conserved 4-amino group of the inhibitor. Comparisons between structures of
wild-type SaDHFR and those with the F98Y mutant enzymes show that the F98Y
mutation induces a rotation of the Phe 92 backbone carbonyl by 1.1 Å, which disrupts the
hydrogen bond between the carbonyl oxygen and the N4-amino group of the
diaminopyrimidine ring (Figure 3). The hydrogen bond between the Phe 92 carbonyl and
the 4-amino group in the wild-type enzyme is 2.9 Å; in the mutated structure it is 3.9 Å.
There is a new hydrogen bond between Tyr 98 and the 4-amino group, but with reduced
strength (3.4 Å). Loss of this conserved hydrogen bond to Phe 92 would represent a
significant loss in affinity.
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Figure 3 The shift in the position of the carbonyl of Phe 92 in the F98Y mutant (cyan)
eliminates a hydrogen bond to the 4-amino group of the inhibitor. The black bar
represents the 1.1 Å shift. The water molecule bound to the nicotinamide ring of αNADPH and Phe 92 is shown.

The presence of the Asn 30 mutation results in the re-organization of a water network
between the active site residues and the inhibitor, effectively eliminating a hydrogen bond
between the pyrimidine ring and protein. In the structure with wild-type SaDHFR, a critical
water molecule bound to the N2-amino group of the diaminopyrimidine (2.9 Å; cyan in
Figure 1c) is involved in a water network with the backbone carbonyl of Tyr 109 (2.8 Å)
and the imidazole side chain of His 30, effectively tying the diaminopyrimidine to two
protein residues (Figure 4). In fact, the distance of this water molecule bound to His 30 is
quite conserved, having an average value of 2.9 Å over several SaDHFR:PLA crystal
structures. In the structures with the Asn 30 mutation, the water molecule (magenta in
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Figure 4) more closely coordinates with the mutated Asn residue instead of the inhibitor,
reducing the effective hydrogen bonding interactions of the inhibitor. Measurements of the
distance of the water molecule to the 2-amino group show that the bonds are 3.4 Å and
3.5 Å in the SaH30N and Sa(F98Y/H30N) structures, respectively; these distances are
too far to create effective hydrogen bonds. This disruption of the water network linking the
inhibitor to the active site residues is similar to that reported in our earlier structure7.

Figure 4 Two water molecules (blue and red) tie the pyrimidine ring to His 30 (wt) and Tyr
109. The H30N mutation (magenta) pulls one of the water molecules (magenta) 1 Å away
from the 2-amino group, eliminating the hydrogen bond.

The double mutant enzyme, F98Y/H30N shows both the shifted carbonyl for Phe 92 as
well as the altered water network at Asn 30, greatly decreasing the hydrogen bonding
interactions of the 2- and 4-amino groups of the pyrimidine ring. There is a prominent

96

functional synergy between these two mutations. Not only does the second mutation
further weaken inhibitor binding by disrupting contacts at the pyrimidine ring, but also
restores the catalytic activity of the enzyme to near wild-type values (Table 2). The two
cooperative effects provide a powerful mechanism for the organism to become drug
resistant.

In general, the PLAs show significantly increased potency for the mutant enzymes
relative to TMP. One reason for this increased potency is the coordination of a water
molecule, observed in both the F98Y and F98Y/H30N structures, between the
carboxylate group on UCP1106 and Arg 57 (2.5 Å) (Figure 5). The extra hydrogen bonds
created by the coordinated water molecule and Arg 57 compensate for interactions lost
by the pyrimidine ring. The presence of the tricyclic a-NADPH anomer indicates a
potentical beneficial relationship between PLA activity and novel anomer. The displaced
nicotinamide of tNADPH coordinates a water molecule (2.4 Å) that stabilizes the carbonyl
of Phe 92 (3 Å), preserving the hydrogen bonding interactions between Phe 92 and the
inhibitor (Figure 3). β-NADPH does not coordinate this water molecule, does not stabilize
the Phe 92 carbonyl and effectively allows the loss of the hydrogen bond.
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Figure 5 A water molecule forms hydrogen bonds between the carboxylate and Arg 57

4.6 Conclusions
Through generation, selection and analysis of UCP1006R S. aureus mutants, the
biochemical and molecular mechanisms of resistance via point mutations can be
evaluated. By focusing on a panel of strains containing dfrB mutations that have clinically
identified as TMP resistance determinants, discovery efforts can be focused on
overcoming modifications that the enzyme has known to accommodate with minimal
fitness losses. Overall, the mutation frequency for the PLAs is very low with frequencies
between 10-10 and 10-11. A series of fitness experiments show that the mutant enzymes
and strains, especially double mutants, are as fit as wild-type. Evaluation of TMP and a
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series of twelve PLAs shows that the PLAs are generally much more potent than TMP
against both the mutant enzymes and strains. Specifically, the PLAs possessing a
carboxylate moiety exhibited good potency against the difficult double mutant enzymes
and strains.

Crystal structures of UCP1106 bound to NADPH and SaDHFR, Sa (F98Y), Sa (H30N)
and Sa (F98Y/H30N) show that the mutations specifically diminish the binding of the 2and 4-amino groups on the pyrimidine ring through nuanced changes in the water
networks. The carboxylate moiety forms hydrogen bonds, water mediated in the case of
UCP1106, with an active site arginine, compensating for some of the lost pyrimidine
interactions and restoring affinity to the mutant enzymes. Overall, the PLA-COOH
compounds appear to be excellent lead compounds that maintain potency for wild-type
enzymes and strains while overcoming resistance features in mutant enzymes and
strains, further indicating that optimization of this class of compounds can overcome
future enzymatic modifications.
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Chapter 5
Understanding and Overcoming Clinical Trimethoprim Resistance

5.1 Clinical Trimethoprim/Sulfamethoxazole Resistance
Resistance to trimethoprim began developing over a decade after its introduction to the
clinic in 19621,2. A single TMPR S. aureus strain from Switzerland revealed the first clinical
TMPR determinant, an innately resistant plasmid-acquired DHFR enzyme. The gene,
dfrA, located on a mobile genetic element, encodes a highly resistant DHFR enzyme
commonly referred to as S1 DHFR (here referred to as DfrA).

DfrA is believed to

originate from Staphylococcus epidermidis, as it contains three mutations: V31L, G43A
and F98Y when compared to its TMPS endogenous DHFR2. DfrA and DfrB share an 80%
sequence similarity. In 1997, point mutations in the endogenous DHFR (DfrB), (including
F98Y as well as H30N, F98Y and F98Y, H149R), discussed extensively in Chapter 5
were identified as clinical TMPR determinants3.

More recently, two additional TMPR dfr isoforms were identified in S. aureus clinical
isolates. The first gene, dfrG, encoding an innately resistant DHFR enzyme (DfrG), was
initially identified in Thailand4 followed by reports of its wide spread throughout subSahara Africa5. This latter study monitored the import of the gene to Europe through
people traveling from Africa. Finally, DfrK, encoded by the gene dfrK, were detected in
farmers and children living near rural, highly agricultural regions in Ireland6. DfrK, which
shares a 90% sequence identity with DfrG, had been widely reported in pathogenic
strains of porcine and livestock S. aureus, prior to its identification in human pathogens7,8.
DfrG and DfrK only share a 38% sequence identity to DfrA and 40% to DfrB. Like dfrA,
dfrK and dfrG are located on highly mobile genetic elements and incorporated into the

101

chromosomes via horizontal gene transfer. Despite knowledge of the existence of the
plasmid-encoded resistance elements dfrG and dfrK, their importance in clinical strains of
MRSA and MSS Awas not thought to be significant. Therfore, antifolate development was
more targeted toward the accumulation of resistant mutants of the chromosomal gene.

Recent surveillance reports indicate a regional variance in resistance rates for TMP,
whereas US hospitals report rates of 2-3% for TMP/SMX9, European travel clinics report
rates of up to 50% for TMP and 19% for TMP/SMX5. There has be no recent survey of the
molecular mechanism of resistance to TMP or TMP/SMX in United States hospitals. Until
this point, we have been pursuing the design of inhibitors that overcome mutational
resistance with the intentions of creating broad activity against current, clinically relevant
TMPR strains. Initial success of the class of carboxylate PLAs against series the TMPR
mutant enzymes and strains, specifically ones containing F98Y, validates these design
efforts. As antibiotic resistance is constantly evolving, it is crucial to identify the
contemporary mechanisms of resistance in order to further develop potent lead
compounds. Presented in this chapter is the investigation into the molecular mechanisms
of TMP resistance in S. aureus isolates from Connecticut hospitals and efforts to identify
inhibitors that directly inhibit the predominating mechanisms of resistance.

5.2 Characterization of TMPR Clinical Isolates
Over a two-year period, more than 30 TMPR S. aureus isolates were obtained from the
clinical microbiology laboratories at UConn Health/John Dempsey Hospital (UCH) and
Hartford Hospital (HH). These strains were isolated in the course of routine clinical care
and originally submitted for routine susceptibility testing. The strains were collected from
different patients, were isolated from a variety of sources including blood, skin and soft
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tissue (SSTI), sputum (lung) and the sinus cavity and feature diverse antibiotic resistance
genotypes. The blood sample was derived from a hospitalized patient; the other isolates
were outpatient derived. TMP/SMX resistance rates at UCH and HH are reported at <1 %
and 2% for MSSA and 2-3% and 5% for MRSA isolates, respectively.

The first obtained clinical isolates, UCH MRSA 1-10, revealed high levels (MIC >
1mg/mL) of TMP resistance (Table 1). Initial investigations into the TMPR mechanisms
indicated that all strains contained a WT, TMPS endogenous DHFR (dfrB) and the lack of
the well-characterized dfrA gene was confirmed by PCR. In order to explore further, we
initially conducted whole genome sequencing on a single strain, UCH MRSA 1. Genomic
analysis revealed the presence of a second, chromosomally incorporated DHFR enzyme
encoded by the gene, dfrG that had been integrated into the chromosome. To our
knowledge, this is the first report of dfrG in North America. We then used PCR to evaluate
the remaining strains for their dfrB sequences and the presence of dfrG as well as two
other plasmid-encoded genes, dfrA and dfrK, known to occur in S. aureus2,6,11.
Surprisingly, we found that all of the clinical isolates carried one of the plasmid-encoded
genes, with dfrG predominating in 78% of strains. We also identified, for the first time in
the United States, the presence of the dfrK gene. dfrA appeared in the remaining strains.
Given the limited number of strains and hospitals represented here, the occurrence of
these diverse, previously unreported resistance elements are striking.

103

Table 1 Characterization of All TMPR Clinical MRSA Isolates
Strain

Source

dfrB

TMPR

Strain

Source

dfrB

element

TMPR
element

UCH 1

Blood

WT

dfrG

UCH124

Urine

WT

dfrG

UCH 2

Sputum

WT

dfrG

UCH 126

Wound

WT

dfrG

UCH 5

Sputum

WT

dfrG

UCH127

SSTI

WT

dfrG*

UCH 6

Urine

WT

dfrG

UCH128

SSTI

WT

dfrG

UCH 7

Sputum

WT

dfrG

UCH129

Wound

WT

dfrG

UCH 8

Sputum

WT

dfrG

UCH130

SSTI

WT

dfrG

UCH 9

Feces

WT

dfrG

UCH131

Urine

WT

dfrG

UCH 10

Sputum

WT

dfrG

UCH132

Blood

WT

dfrG

UCH115

SSTI

WT

dfrA

HH553

Sputum

WT

dfrA

UCH116

SSTI

WT

dfrA

HH601

Blood

WT

dfrG

UCH117

Urine

WT

dfrG

HH714

SSTI

WT

dfrG

UCH118

SSTI

WT

dfrA

HH1144

SSTI

WT

dfrA

UCH119

SSTI

WT

dfrG

HH1155

Sputum

WT

dfrG

UCH120

Trachea

WT

dfrG

HH1184

Sputum

WT

dfrK

UCH121

Sputum

WT

dfrG

HH1251

SSTI

WT

dfrA

UCH123

Wound

WT

dfrG

MSSA 1

Sinus

WT

dfrG

* Strain is SMXS, which presents as BactrimS clinically

A panel of eight strains, based on their antibiotic phenotypes, was selected for a more indepth microbiological, biochemical and genetic analysis. Seven of the selected strains
were classified as MRSA and one additional was MSSA; the methicillin resistance
classifications were based on clinically determined susceptibilities. All three of the
innately resistant DHFRs are represented in the panel of isolates (Table 2, Figure 1). The
fitness of the strains, as measured by doubling time, doesn’t appear to be any affected by
harboring these extra genes as the doubling times were generally shorter than the ATCC
43300 strain (Table 2).
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Figure 1 Composite gel showing PCR products depicting the presence of dfrG, dfrA, dfrK
and dfrB in the UCH and HH strains.

While each of the strains is highly resistant to TMP, they have variable
susceptibilities SMX, with MIC values between 250 and >1,000 µg/mL or 15-500 µg/mL,
respectively. UCH MRSA 127, which contains dfrG but is SMX susceptible presents
clinically as BactrimS with the MIC at the clinical breakpoint. This point can convolute the
surveillance TMPR statistics in clinical labs that only screen for Bactrim resistance. In
addition to TMP and SMX, strains show varying resistance profiles to a wide range of
commonly used antibiotics including erythromycin, fluoroquinolones, aminoglycosides
and tetracycline (Table 3).
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Table 2 Characterization of Select TMPR Clinical Isolates
TMP

TMP

SMX MIC

Doubling

MIC

(μg/mL)

Time (min)

>1,000

>500

40.33

WT

250

500

35.19

dfrG

WT

>1,000

>500

28.17

SSTI

dfrG

WT

>1000

15.625

38.61

HH 714

SSTI

dfrG

WT

>1000

>500

27.39

HH 1144

SSTI

dfrA

WT

250

>500

32.54

HH 1184

Sputum

dfrK

WT

>1000

>500

29.38

UCH MSSA 1

Sinus Cavity

dfrG

WT

>1000

>500

36.49

Sa43300

ATCC

None

WT

0.3125

10

38.16

Strain

Infection

Designation

Source

UCH 1

Blood

dfrG

WT

UCH 115

SSTI

dfrA

UCH 121

Sputum

UCH 127

Resistant

dfrB

Gene

(μg/mL)

To better understand the possible relationships between these strains, the genetic
diversity was determined through sequencing and typing of the spaA gene12. The analysis
showed that five of the strains (UCH MRSA115, UCH MRSA121, UCH MSSA1, HH
MRSA714 and HH MRSA1144), including strains from both hospitals and the MSSA
strain, were clonally indistinguishable. However, UCH MRSA127, HH MRSA1184 and
UCH MRSA1 are clonally distinct isolates. Importantly, within the group of five clonal
isolates, dfrA and dfrG are represented and dfrK is found the distinct yet related strain,
HH MRSA 1184, Figure 2. The appearance of the different dfr isoforms within the closely
related cluster as well as more genetically distinct strains suggests that they are on
potentially highly mobile resistance elements.
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Figure 2 Clonal characterization of S. aureus strains by spaA sequencing

5.3 Clinical Isolates Exhibit a Range of Antibiotic Susceptibilities
The phenotypes to commonly prescribed non-TMP antibiotics were determined for the
panel of isolates revealing diverse variability in susceptibilities. All strains were
susceptible to vancomycin, linezolid, rifampin and daptomycin and have varied
susceptibilities to sulfamethoxazole, erythromycin, clindamycin, tetracycline, gentamicin
and a variety of fluoroquinolones, based on breakpoint MICs (Table 3).

To better

understand the diversity of the isolates, the remaining seven genomes were sequenced
and the molecular mechanisms of resistances were identified. The only resistance
mechanism that mirrors the clonality pattern is found with sulfamethoxazole; the group of
five clonal strains contained five previously reported folP mutations (F17L, T28S, T59S,
L64M, E205K) conferring high-level SMX resistance. Whereas, UCH 1 contains thirteen
folP mutations (F17L, V30I, T31N, M37I, I58V, T59S, V60L, L64M, I110M, V117I, V126I,
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E208K, F226L) and HH1184 contains nine (V30I, I58V, T59S,V60L, L64M, I100M, V117I,
V126I, F226L)13.

Table 3 Antibiotic Susceptibility Profiles of Clinical MRSA Isolates (μg/mL)
Strain

Erythromycin

Clindamycin

Tetracycline

Gentamicin

Levofloxicin

UCH 1

>4 (R)

<0.12 (S)

<2 (S)

<2 (S)

64 (R)

UCH 115

<0.25 (S)

<0.12 (S)

>16 (R)

>16 (R)

>64 (R)

UCH 121

>4 (R)

0.25 (S)

<2 (S)

<2 (S)

>64 (R)

UCH 127

>4 (R)

<0.12 (S)

<2 (S)

<2 (S)

8 (R)

HH 714

2 (R)

<0.12 (S)

<2 (S)

<2 (S)

>64 (R)

HH 1144

>4 (R)

>2 (R)

>16 (R)

>16 (R)

8 (R)

HH 1184

>4 (R)

0.25 (S)

<2 (S)

<2 (S)

0.25 (S)

UCH MSSA 1

>4 (R)

>2 (R)

<2 (S)

<2 (S)

8 (R)

TetM, a ribosome protection protein, is identified as the tetracycline resistance
determinant observed in UCH115 and HH114414. Gentamicin resistance in UCH115 and
HH1144 is conferred by a plasmid borne AAC(6’)-APH(2”) aminoglycoside resistance
enzyme15.

Tetracycline and aminoglycoside resistance was only identified in strains

containing dfrA, however these strains differ both in fluoroquinolone resistance
mechanisms and macrolide susceptibility. mphC, a 2’-phosphotransferase which directly
inactivates the macrolides via phosphorylation determines selective macrolide resistance
(erythromycin) in UCH MRSA121, UCH MRSA127 and HH MRSA1184, all clonally
distinct isolates20,21. mphC is not commonly reported to confer macrolide resistance in
human S. aureus isolates, instead it is more frequently reported in agricultural studies22.
ermC, a 23s rRNA methyl transferase, found in UCH MRSA 1, HH MRSA 1144 and UCH
MSSA 1 confers resistance to both macrolides and lincosamines (clindamycin)23.
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Resistance to fluoroquinolone in all strains except HH MRSA1184 is conferred through a
variety of mutations in the quinolone resistance-determining regions (QRDRs) of DNA
gyrase subunit A (gyrA) and topoisomerase IV, subunits A and B (grlA and grlB). The
combinations of mutations vary from single gyrA mutations to the accumulation of four
mutations between gyrA, grlA, and grlB were observed16,17. NorA efflux activity in
fluoroquinolone resistance was determined by MIC in the presence of reserpine, a NorA
inhibitor. Minimal shifts in MIC for levofloxacin and up to 8-fold decrease in ciprofloxacin
MIC indicate that NorA has minimal influence on fluoroquinolone resistance (Table 4)18,19.

Table 4 Minimum Inhibitory Concentrations with 20 µg/mL Reserpine (µg/mL)
Minimum Inhibitory

Minimum Inhibitory Concentration

Concentration

20 µg/mL Reserpine

Strain

Levofloxacin

Ciprofloxacin

Levofloxacin

Ciprofloxacin

UCH 1

64

>64

64 (1)

32 (>2)

UCH 115

>64

>64

>64 (>1)

32 (>2)

UCH 121

>64

64

>64 (>1)

32 (2)

UCH 127

8

32

4 (2)

8 (4)

HH 714

>64

64

>64 (>1)

32 (2)

HH 1144

8

64

8 (1)

16 (4)

HH 1184

0.25

1

<0.125 (>2)

<0.125 (>4)

UCH MSSA 1

8

64

8 (1)

32 (2)

Fold increases in MIC noted in parenthases

HH MRSA 1184 is the only strain to contain the Panton-Valenitine leukocidin, a virulence
factor that produces a cytocoxin associated with tissue necrosis and leukocyte damage24.
All strains clinically classified as ‘methicillin resistant’ via susceptibility are mecA positive.
A full list of target mutations and resistance determinants are summarized in Table 5.
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Table 5 Molecular Mechanisms of Antibiotic Resistance for Clinical Isolates
MIC Range

Resistance Mechanism

Trimethoprim

(ug/mL)

Strains

dfrA

250

UCH115, HH1144

dfrG

>1000

dfrK

>1000

HH1184

>500

UCH 1

UCH

1,

UCH121,

UCH127,

HH714, UCH MSSA1

folB(F17L, V30I, T31N, M37I,
I58V, T59S, V60L, L64M,
I110M, V117I, V126I, E208K,
F226L)
Sulfamethoxazole

folB(F17L, T28S, T59S, L64M,
E205K)

>500

UCH 115, UCH 121, UCH127,
HH714, HH1144, UCH MSSA1

folB (V30I, I58V, T59S,V60L,
L64M, I100M, V117I, V126I,

32

HH1184

F226L)
Tetracycline

TetM

>16

UCH115, HH1144

Gentamicin

aac(2’)-apc(6”)

>16

UCH115, HH1144

mphC

8-32

UCH121, UCH127, HH1184

ermC

>64

UCH 1, HH 1144, UCH 1

ermC

>64

UCH 1, HH 1144, UCH 1

Erythromycin
Clindamycin

gryA(S84R ,S85P),
grlA(S80F), grlB(E471K)
gryA(S84L, S85P), grlA(S90K,
Levofloxacin/

E84K)

Ciproflxacin/

gryA(S84R ,S85P),

Gatifloxacin

grlA(S80F), grlB(D432V)

UCH 1

>64/>64/ >8

UCH115

>64/64/>8

gyrA (S84L) and grlA (S80F),
grlB(D432V, E596D*)
gyrA (S84L) and grlA (S80F)
Levofloxacin/
Ciproflxacin

64/ >64/>8

gyrA(S84L)

8/32/4

UCH127

8/64/4

HH1144

8/64
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UCH121, HH714

UCH 1

5.4 Propargyl-linked Antifolates Potently Inhibit Clinical Isolates
Whole genome sequencing of the clinical strains showed notable variation in the
molecular basis of TMP resistance as well as several common antibiotics. This provided a
useful panel of clinically relevant strains that can be used as an important tool for lead
optimization. Therefore, we screened a variety of previously developed PLA lead
compounds against the panel of TMP-resistant strains to identify candidates with broad
activity. Excitingly, several of the compounds (UCP1039, UCP1164, UCP1172, UCP1173
and UCP1175; Table 5, Figure 3) showed very potent activity against these highly TMPresistant strains. Although we observed activity with earlier generation inhibitors that
contained a pyridyl C-ring (eg. UCP1039) the most potent activity was observed with a
recently disclosed charged/zwitterionic series possessing an ionizable carboxylic acid on
the distal C-ring (UCP1164, UCP1172, UCP1173 and UCP1175). Overall, the PLAs were
most potent against strains carrying dfrG and dfrK with MIC values as low as 0.1563
µg/mL, two-fold lower than the MIC for TMP against wild-type S. aureus. Compound
UCP1173 showed the most potent activity against strains possessing dfrA with MIC
values of 1.25 and 2.5 µg/mL. Interestingly, compound UCP1172 is the antipode of
UCP1173 but does not significantly inhibit dfrA-possessing strains.
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Figure 3 Structure of TMP and PLAs Described in this Chapter

Table 6 PLA Antibacterial Activity against Clinical Isolates (MICs in µg/mL)
Inhibitor

UCH 1

UCH

UCH

UCH

HH

HH

HH

UCH

ATCC

(dfrG)

115

121

127

714

1144

1184

MSSA

43300

(dfrA)

(dfrG)

(dfrG)

(dfrG)

(dfrA)

(dfrK)

1
(dfrG)

UCP1039

1.25

>20

0.625

0.3125

1.25

>10

1.25

0.625

0.0391

UCP1164

2.5

10

5

2.5

5

5

0.625

5

0.0391

UCP1172

0.625

5

0.625

0.3125

0.625

5

0.3125

0.3125

0.0098

UCP1173

5

2.5

5

2.5

5

1.25

2.5

2.5

0.0098

UCP1175

2.5

>20

10

5

10

>20

5

10

0.0195

UCP1191

0.625

20

0.625

0.1563

0.625

10

0.1563

0.3125

0.0195

UCP1205

0.625

>10

0.625

0.3125

0.625

>10

0.3125

0.3125

0.0195

UCP1206

2.5

>10

2.5

1.25

2.5

>10

1.25

1.25

0.0098

UCP1191

0.0391

00.625

0.0781

0.3125

0.0391

0.625

<0.0048

0.0098

<0.0048

+SMXa
a

MIC values with 100 µg/mL Sulfamethoxazole (SMX), ATCC 43300 and UCH 127 at 1

µg/mL SMX
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It was noted that C3’, C4’ dioxygenation with a pyridyl C-ring (UCP1039) afforded some of
the strongest activity in this series and as such, we investigated combining this pattern of
functionality with the preference for a C-ring carboxylic acid. To explore this design, a
dioxalane ring was chosen as a convenient isostere as it afforded antibacterial activity
against strains that possessed a DHFR with the F98Y mutation25. The racemic inhibitor
UCP1191 and the individual enantiomers, UCP1205 and UCP1206, were therefore
synthesized and evaluated. We were delighted to see a significant increase in activity
against both dfrG- and dfrK-possessing strains with MIC values of 0.1563-0.625 µg/mL.
Interestingly, despite these strains also being SMX-resistant, an apparently strong
synergistic interaction between the PLAs and SMX was observed (Tables 6 and 7).

Table 7 Minimum Inhibitory Concentrations with 100 µg/mL Sulfamethoxazole (µg/mL)
Strain

UCP1039

UCP1164

UCP1172

UCP1173

UCP1191

UCP1205

UCP1206

UCHC 115

dfrA

1.25

0.3125

1.25

0.1563

0.625

2.5

0.625

HH 714

dfrG

0.0391

0.3125

0.3125

0.3125

0.0391

0.0391

0.1563

HH 1184

dfrK

<0.0048

<0.0048

<0.0048

<0.0048

<0.0048

<0.0048

<0.0048

Cloning, expressing, purifying and evaluating enzyme inhibition provided further validation
that antibacterial activity of the PLAs in these resistant organisms was directly related to
their ability to inhibit the resistance-conferring enzymes. The three genes, dfrA, dfrG and
dfrK were cloned into expression vectors and the resulting proteins purified to
homogeneity. The PLAs were evaluated for enzyme inhibition using standard assays that
measure the oxidation of the NAPDH cofactor (Table 7)25,26. As expected, TMP exhibits
high inhibition concentration 50 % (IC50) values for all three TMP-resistant DHFRs.

113

Despite the fact that there has been no directed optimization of the PLAs against these
TMP-resistant proteins, the PLAs showed relatively potent inhibition with the majority of
IC50 values less than 100 nM, highlighting the value of our approach to use structurebased targeting of common resistance mechanisms in DHFRs25,27. Remarkably, this is
an approximately 4400-, 55-, or 2000-fold increase in potency over TMP for the DfrG,
DfrA and DfrK proteins, respectively. Although a variety of factors beyond target inhibition
contribute to the overall antibacterial activity, there is a correlation between PLA activity
against the TMP-resistant enzymes and the MICs against the corresponding strains.
Additional validation that the PLAs exert their antibiotic effect through blockade of the
folate pathway was provided by rescue experiments, where the culture media was
supplemented with thymidine and MIC values rose by at least 8-fold (data not shown).

Table 8 Enzyme Inhibition (IC50 values shown in µM)
Inhibitor

DfrB

DfrG

DfrA

DfrK

TMP

0.023 + 0.002

380 + 12

15.1 + 0.7

43 + 2

UCP1039

0.014 + 0.001

0.45 + 0.02

0.36 + 0.02

0.022 + 0.003

UCP1164

0.037 + 0.002

1.4 + 0.1

8.8 + 0.9

0.073 + 0.002

UCP1172

0.0089 + 0.0007

0.22 + 0.02

0.41 + 0.01

0.030 + 0.001

UCP1173

0.014 + 0.001

0.19 + 0.01

0.27 + 0.02

0.091 + 0.008

UCP1175

0.0110 + 0.0006

1.4 + 0.2

0.98 + 0.008

0.17 + 0.01

UCP1191

0.010 + 0.0002

0.087 + 0.005

0.32 + 0.03

0.041 + 0.006

UCP1205

0.018 + 0.003

0.159 + 0.007

0.34 + 0.01

0.10 + 0.01

UCP1206

0.017 + 0.002

0.19 + 0.01

0.18 + 0.03

0.054 + 0.005
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5.5 Structural Basis of Activity of PLAs in Clinical Isolates
Analysis of the crystal structures of the potent inhibitors, UCP1175 and UCP1191,
complexed with DfrB and NADPH reveal a structural basis for activity of these inhibitors.
It appears that the binding position of the inhibitors, influenced on substitutions at both the
propargyl positions and the B-ring, is critical for achieving potent activity. The carboxylate
moiety of UCP1191 forms one direct ionic bond to Arg 57 and one water-mediated
hydrogen bond to Arg 57 and Lys 32, wherase UCP1175, which lacks the methyl
substitution at the propargly position, forms an extensive water network with Arg 57 and
carboxylate28. Furthermore, the structure of UCP1106, which retains no activity in these
resistant enzyme shows a water mediated interaction between the PLA and the enzyme.
In this structure, however, the water is more closely associated with the PLA and does
not form a proper interaction with Arg 57.

It appears that the propargyl methyl of UCP1191 pushes the biphenyl system further into
the active site and within bonding distance to Arg 57 and the lack of substitution at the
propargyl position and 2’ B-ring positions allows for the formation of an evenly dispersed
water network, as there is a greater distance between Arg 57 and the carboxylate.
UCP1106, which binds in an intermediate position, dictated by the 2-OMe B-ring
substitution, does not allow for the even water formation and therefore forms a less stable
complex with the enzyme (Figure 4). Arg 57 is conserved in all of the TMP-resistant
enzymes (Figure 5) and forms a similar key contact with dihydrofolate, suggesting that
this contact is less likely to mutate to cause resistance to the PLAs.

115

Figure 4 a) Water mediated binding interactions of UCP1175 (green) compared to the
binding of UCP1191 (blue). b) Binding interactions of UCP1106 (magenta) compared to
the binding of UCP1191 (blue). All inhibitors are co-crystallized with DfrB and NADPH.

The TMP-resistant enzymes tend to conserve their mechanisms of reducing TMP affinity
(Figure 5). Leu 5 is an isoleucine in the TMP-resistant enzymes; this mutation would
disturb Phe 92, which is critical both for hydrogen bonding to 4- amino group of the
diaminopyrimidine as well as hydrophobic interactions with the linker. Leu 28 is a tyrosine
in DfrG and DfrK and Val 31 is Ile in DfrA; these mutations also perturb Phe 92 (38). The
Val 31 Ile mutation was predicted by K* in the OSPREY suite to cause resistance to an
earlier PLA, and in fact reduced affinity by 60-fold29. Crystal structures of the double
mutant enzyme, F98Y/V31I, show the perturbation of Phe 92. His 30 mutations have
been observed clinically and studied extensively in the dfrB gene3. While the mutation His
30 Asn has been shown to disrupt the water network stabilizing the pyrimidine ring27, 30,
the TMP-resistant enzymes DfrK and DfrG carry a tyrosine at this position, which may
achieve the same goal. Finally, all three TMP-resistant enzymes maintain a tyrosine at
position 98 (wt Phe). The tyrosine has been shown to perturb NADPH binding25,26 and to
decrease synergistic binding between TMP and NADPH31. Previous design efforts
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focused on achieving inhibitor potency against the mutations observed in the
chromosomal copy, dfrB, such as the Phe98Tyr-mutated DHFR enzyme25,27,31,32.

Figure 5 Protein sequence alignment of the dfr isoforms. Interesting amino acids are
highlighted in red.

These efforts may prove valuable as the TMP-resistant enzymes DfrG, DfrK and DfrA all
possess a tyrosine residue at position 98. As shown here, designing inhibitors against
the F98Y chromosomal mutant provided a significant advantage in achieving superior
potency against these resistant enzymes, as they appear to rely on common
mechanisms.

Recently, we described potent activity of the COOH-PLA series,

specifically UCP1164, UCP1172, UCP1173 and UCP1175 against strains containing
these clinically relevant point mutations in dfrB. Including F98Y, H30N/F98Y and
F98Y/H149R. While the COOH-PLAs are more potent against the single F98Y mutant
strain than the acquired dfr isoforms, UCP1164 and UCP1172 maintain superior activity
against the acquired resistance elements over the double mutants27. The remaining
compounds display similar inhibitory activity in the acquired and mutant DHFR enzymes.
As the mutations that confer TMP resistance appear to belong to a conserved and
relatively manageable group, future design efforts can capitalize on this group to optimize
ligands that inhibit the majority of clinically observed TMP-resistant species.
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5.6 Conclusions
By investigating the contemporary mechanisms of TMP resistance, we are able to show,
within a small collection of clinical TMPR S. aureus isolates, the surprising preponderance
of TMPR elements that have never been identified domestically. Genomic analysis of the
strains indicates an even wider diversity of mechanisms and susceptibilities to commonly
used antibiotics. This genetic analysis of the strains is representative of the extensive
spread of antibiotic resistances and supports the thoughts that these elements are easily
transferred between bacteria, suggesting that occurrence of these genes may be much
wider than reported.

Only by understanding the structural mechanisms of TMP resistance are we able to
continue design of propargyl-linked antifolates that potently inhibit both TMP-resistant
enzymes and the strains harboring these elements. Here, the identification of the dfrA,
dfrG and dfrK genes in clinical isolates has validated the efforts to design robust inhibitors
that can overcome mutational changes in the enzyme. These efforts have yielded a class
of carboxylate substituted PLAs that exhibit unprecedented activity directly against these
highly resistant elements, resensitizing these antifolate resistant strains to PLAs.
Furthermore, the clinical relevancy of the compounds remains acute as timely clinical
data drive compound design.
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Chapter 6
Final Analysis and Future Directions

6.1 Continued Development of Propargyl-linked Antifolates
Through the process of structure based drug design, a class of novel antifolates has been
optimized against S. aureus DHFR enzymes. Adding an acetylene linker and building the
compounds from simple trimethoprim derivatives and exploiting crucial enzymatic
interactions through rational inhibitor modifications has lead to a diverse library of
propargyl-linked antifolates. It is shown that combination of RP, B-ring and C-ring
substitutions can lead to highly favorable interactions that translate into increased cellular
and enzymatic potency. Specifically, compounds with R1-OMe substitutions on the
carboxylate PLA scaffold results in reduced potency compared to the R2 and R2/R3
positions when a RP methyl is present. Crystal structures indicate that the RP methyl
dictates the binding position when no R1 substituent is present and provides an optimal
orientation for direct ionic interactions with Arg 57. Currently, the most potent compounds
in this class make one direct and one water mediated interaction with Arg 57. Additional
modifications to the compounds, including exploring C-ring substituents and B-/C-ring
linkers can optimize the interaction between the carboxylate and Arg 57 guanidinium to
better mimic DHF. Overall, these compounds are selective for the pathogenic enzymes
over the human isoform and maintain activity regardless in S. aureus associated DHFR
enzymes regardless of their identity.

A single crystal structure of UPC1191, a RP-methyl substituted p-COOH indicates the
important role of the propargylic methyl in the carboxylate series of PLAs. Comparisons of
this structure with structures co-crystallized with UCP1106 and UCP1175 (hydrogensubstituted RP) indicates that this substituent is crucial for optimized interactions with the
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enzyme. Additional crystal structures of an enantiomer pair, for example UCP1172 and
UCP1173 or UCP1205 and UCP1206, would elucidate differences in the pyridine and
carboxylate substituted enantiomers. It is believed that the presence of the carboxylate
and its hydrogen bonding abilities will dictate the binding position of the biaryl system as
opposed to the distinct binding of the pyridine enantiomers. In this case, enantiomerically
pure compounds would not be necessary for optimized potency, reducing both costs and
time during PLA development.

In addition to being potential therapeutic candidates, these small molecule inhibitors can
also be used as probes into the structure and function of the DHFR enzymes. Specifically,
stereospecific modifications to the propargylic position can influence both the cofactor
and biphenyl system binding. Through investigations with these compounds, it has been
discovered that the cofactor-binding site can accommodate an alternative configuration,
indicating plasticity and flexibility of the protein. Continued investigations to the
mechanism by which this alternate cofactor is generated and its biological relevance
should be pursued. The β- to α-NADPH anomerization requires a ring opening and ring
closing mechanism, which occurs at an equilibrium that heavily biases the β-anomer.
However, the tautomerization of the α-NADPH to the closed-ring tricyclic NADPH
analogue does not occur under typical thermodynamic and chemical environments.

It is believed that the extended α-NADPH binds the tertiary PLA/ enzyme complex and
PLA binding induces the reorientation of the internals NAPDH phosphates stabilizing the
tricyclic NADPH intermediate. Once stabilized, the enzyme can facilitate the cyclization
reaction if oriented correctly with charged side chains1. Conversely, t-NADPH might be
generated in solution under crystallization conditions and recruited to the active site,
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however due to variances in the crystallography conditions this option is less likely.
Crystal structures indicate that shifts in the acetylene linker binding position correlates
with identity of NADPH recruited to the active site. Understanding whether or not the PLA
binding positions and alternative NADPH is an artifact in crystallography or a product of
PLA binding should be investigated. Experiments that quantitatively look for the
conversion of β-NADPH to t-NADPH in solution with the enzymes and PLA can be
designed, following standard biotransformation protocols and measured using analytical
methods2.

6.2 Understanding Antifolate Resistance
A comprehensive evaluation of resistance during the development of PLAs against
trimethoprim resistant S. aureus lead to a better understanding of antifolate resistance.
These efforts include prediction and prospective mutational resistance and determination
of the contemporary mechanisms of clinical TMP resistance. During these studies we
identified a series of mutations the enzyme can make to evade inhibition to a lead PLA
and determined that these mutations are common among endogenous and acquired TMP
resistance mechanisms. These studies also allowed us to understand the molecular
mechanisms of resistance and not only design inhibitors that show potent activity across
TMPR enzymes but that are also less susceptible to developing mutational resistance.

The discovery of the DfrG and DfrK enzymes in clinical MRSA isolates from Connecticut
hospitals and lack of point mutations resulted in the reevaluation of clinical antifolate
resistance. Until this point, compounds were designed with the understanding that DfrA
and mutations in DfrB were responsible for clinical resistance. However, just because
point mutations weren’t identified in the TMPR enzymes, doesn’t mean that they can’t
124

arise in response to antibiotic pressure and later confer resistance. This study indicated
large diversity in the molecular mechanisms of resistance, even among clonal isolates, for
trimethoprim as well as other common and important antibiotics. In fact, no two strains
shared the same resistances for the antibiotics evaluated. Importantly, the design of PLAs
inhibitors to overcome point mutations resulted a series of compounds that are show
superior potency against these resistant strains, despite their diversity.

It is important to determine the prevalence of these TMP resistance elements. While
unlikely, it is possible that they are contained within these two Connecticut hospitals. By
acquiring TMPR S. aureus isolates from around the country, we can evaluate the
distribution and relevance of these genes. A more comprehensive, nation-wide
epidemiological study would allow for more accurate overall TMPR and specific TMPR
gene clinical frequencies. Due to the ease and accessibility of whole genome sequencing,
it is plausible to sequence and evaluate a sample of isolates for antifolate and other
antibiotic resistances. Additionally, the PLA susceptibiliites can be screened against a
much larger bank of TMPR S. aureus isolates.

The development of the enantio-pure COOH-PLAs, specifically UCP1172, UCP1173,
UCP1205 and UCP1206, showed high potency against TMPR mutants and acquired
DHFR enzymes and are promising lead compounds for continued pre-clinical evaluations.
Prospective mutational resistance of this class should be evaluated against the
endogenous DHFR as well as the plasmid acquired dfrA, dfrG, and dfrK genes. Because
activity of these PLAs largely relies on the ionic interaction between the carboxylate and
Arg57, mutations at this position would likely result in decreased potency of the inhibitor.
However, Arg 57 is crucial for the binding of DHF and mutation of this position would
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likely result in a significant loss in enzymatic fitness. Experiments generating mutations to
these inhibitors against the panel of dfr isoforms would further elucidate their potential
evolution. Additionally, the frequency at which resistance develops in-vitro to these
inhibitors would confirm or reject the design principles of exploiting non-mutational
interactions to avoid resistance generation, especially when compared to their pyridine
counterparts. In these studies, the over expression of DHFR should also be evaluated as
the continued accumulation of mutations would likely result in unfit enzymes; a second
resistance mechanisms would likely arise in this case.

Of the top 25 mutations predicted by K*, the acquired DHFR enzymes contain five of the
predicted resistance conferring amino acids for DfrA, DfrG and DfrK. These mutations
include L5I and V30I for DfrA and L5I, L28W, L20I and V6A for DfrG and DfrK.
Interestingly, the resistance associated amino acids identified by K* in DfrA are both in
top three ranked mutations and the PLAs are much less active against this enzyme. Not
only does this indicate that there are only few modifications that the enzyme can make to
confer resistance, but it also validates the use of these algorithms in early stage drug
discovery efforts.

Unlike DfrA, little is known about DfrK and DfrG. Until these studies, only the crude KM
and TMP IC50 values were previously described3,4. Efforts into determining the structures
of these enzymes in complex with TMP and potent PLAs can be used to elucidate both
the mechanism of resistance for the enzymes against TMP and the mechanism of action
of PLAs. DfrA is less susceptible to TMP (although it confers high levels of resistance)
and less affected by the PLAs, compared to DfrG and DfrK. A biochemical and structural
understanding of these enzymes would greatly aid in the development of antifolates and
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elucidate DfrA’s unique mechanism of PLA resistance allowing for the generation of
inhibitors with potent activity against this stubborn enzyme.

6.3 Conclusions
Structure based drug design efforts for a novel class of antifolates resulted in a series of
potent inhibitors that exhibit selectively potency against antifolate resistant and
susceptible S. aureus.

These efforts required understanding of the enzymatic and

cellular structure activity relationship of the PLAs with the including the importance of
enantio-pure inhibitors. Designing the inhibitors to overcome known clinical DfrB
mutations resulted in a class of compounds that restore antifolate susceptibility to highly
TMPR S. aureus strains. In doing this, we discovered that plasticity in the cofactor-binding
site and identified a novel NADPH configuration believed to exist in response to PLA
binding.

In order to develop PLAs to overcome TMPR, a comprehensive of understanding of
clinical antifolates was required. In doing this, we isolated a panel of strains containing
mutations common to both PLAs and TMP. Investigations into these strains resulted in a
molecular understanding in their mechanisms of resistance as well as the mechanism of
action of a potent PLA. Until this point, point mutations and the acquisition of a single
innately resistant DHFR enzyme were believed to confer clinical resistance. However, our
investigations indicate that a novel gene, dfrG, never previously reported in the United
States, is responsible for the majority of clinical TMP resistance; we were also able to
identify dfrK for the first time as well as the previously described dfrA gene, both of which
occurred as minor determinants. PLAs designed to overcome the point mutations showed
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potent activity against both the resistant enzymes and S. aureus strains, resulting in a
promising class of inhibitors.
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Appendix B Materials and Methods
B.1 Construction, Expression and Purification of Dihydrofolate Reductase
B.1a Generation of Staphylococcus aureus and Mutant Expression Vectors
The generation, expression and purification of DfrB (wild-type S. aureus DHFR),
DfrB(F98Y), DfrB (H30N) and DfrB (F98Y, H30N) DHFR enzymes have been previously
reported1-3. DfrA in pET-41a(+), DfrG in pET-41a(+) and DfrK in pET-24a(+) were
purchased from Genscript. DfrB(WT) and DfrB(F98Y) in pET-41a(+) constructs were used
for the generation of DfrB(H149R) and DfrB(F98Y, H149R) DHFR plasmids via
QuikChange Lightening Site-Directed Mutagenesis Kit (Stratagene) using sense primer
5’-

CTAGATGAGAAAAATACAATTCCACGTAC-3’

and

anti-sense

primer

5’-

CGAATTAAATGTAGAAAGGTACGTGGAAT-3’ following the manufacturer’s instructions.
Mutagenesis was confirmed via Sanger sequencing using primers specific to the T7
promoter.

B.1b Expression and Purification of Dihydrofolate Reductase
The expression and purification of DfrB, DfrB(F98Y), DfrB(H30N), DfrB (F98Y, H30N) in
pET-41a(+) has been previously described1-3.
Expression and Purification of DfrB (H149R) and DfrB (F98Y, H149R)
BL21 (DE3) cells (Invitrogen) were transformed with DfrB (mutants) in pET-41a(+). The
cells were grown to mid-log phase (OD600=0.8-1.0) at 37oC, induced with 1 mM IPTG and
were allowed to grow for an additional 8 hours at 30oC. One liter cell pellets were lysed
using 1x BugBuster (Novagen) and DNase A (ThermoFisher Scientific). Protein was
purified using Ni-NTA agarose using a wash buffer containing 25 mM Tris, pH 8.0, 0.4 M
KCl, 5 mM Imidazole, 5 mM beta-mercaptoethanol and 5% glycerol and protein was
eluted using a buffer containing 25 mM Tris pH 8.0, 0.3 M KCl, 20% glycerol, 0.1 mM
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EDTA, 250 mM imidazole and 5 mM beta-mercaptoethanol. Clean protein was pooled
and desalted using PD-10 columns (GE Healthcare) into a buffer containing 20 mM Tris
pH 8.0, 20% glycerol, 0.1 mM EDTA and 2 mM DTT. Protein was flash frozen and stored
at -80oC.

Expression and Purification of DfrA
BL21 (DE3) cells (Invitrogen) were transformed with dfrA in pET-41a(+). The cells were
grown to mid-log phase (OD600=0.8-1.0) at 37oC, induced with 1 mM IPTG and were
allowed to grow for an additional 18 hours at 20oC. Cells were pelleted and resuspended
to 30 mL using a buffer containing 0.4 M KCl, 25 mM Tris, pH 8.0, 5 mM betamercaptoethanol, 5% glycerol, 100 µg/mL lysozyme, 5 mM imidazole and DNase (Fisher
Scientific) and lysed via sonication. Protein was purified using Ni-NTA agarose using a
wash buffer containing 25 mM Tris, pH 8.0, 0.4 M KCl, 5 mM Imidazole, 5 mM betamercaptoethanol and 5% glycerol and protein was eluted using a buffer containing 25 mM
Tris pH 8.0, 0.3 M KCl , 20% glycerol, 0.1 mM EDTA, 250 mM imidazole and 5 mM betamercaptoethanol. Clean protein was pooled and desalted into a buffer containing 25 mM
Tris pH 8.0, 0.1 mM KCl, 15% glycerol, 0.1 mM EDTA and 2 mM DTT. Protein was flash
frozen and stored at -80oC.

Expression and Purification of DfrG
DfrG in pET-41a(+), synthesized by Genscript, was transformed into BL21 (DE3) cells
(Invitrogen). The cells were grown to mid-log phase (OD600= 0.8-1.0), induced with 1 mM
IPTG and were allowed to grow for an additional 18 hours at 20oC. Cells were pelleted
and resuspended to 30 mL using a buffer containing 0.5 M KCl, 50 mM Tris, pH 8.0, 5
mM beta-mercaptoethanol, 5% glycerol, 0.8 mg/mL lysozyme, 5 mM imidazole and a
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protease inhibitor tablet (Life Technologies) and lysed with two passes through a French
Press. After lysis, the lysate was incubated with DNase and RNase. Protein was purified
using Ni-NTA agarose using a wash buffer containing 25 mM Tris, pH 8.0, 0.4 M KCl, 5
mM Imidazole, 5 mM beta-mercaptoethanol and 5% glycerol and protein was eluted using
a buffer containing 25 mM Tris pH 8.0, 0.3 M KCl, 20% glycerol, 0.1 mM EDTA, 250 mM
imidazole and 5 mM beta-mercaptoethanol. Clean protein was pooled and desalted into
a buffer containing 20 mM Tris pH 8.0, 20% glycerol, 0.1 mM EDTA and 2 mM DTT.
Protein

was

flash

frozen

and

stored

at

-80oC.

Expression and Purification of DfrK
dfrK in pET-24-a(+) was transformed in BL21 (DE3) cells (Invitrogen). The cells were
grown to mid-log phase (OD600=0.8-1.0) at 37oC, induced with 1 mM IPTG and were
allowed to grow for an additional 18 hours at 20oC. Cells were pelleted and resuspended
to 30 mL using a buffer containing 0.4 M KCl, 25 mM Tris, pH 8.0, 5 mM betamercaptoethanol, 5% glycerol, 100 µg/mL lysozyme, 5 mM imidazole and DNase (Fisher
Scientific) and lysed via sonication. Protein was purified using Ni-NTA agarose using a
wash buffer containing 25 mM Tris, pH 8.0, 0.4 M KCl, 5 mM Imidazole, 5 mM betamercaptoethanol and 5% glycerol and protein was eluted using a buffer containing 25 mM
Tris pH 8.0, 0.3 M KCl , 20% glycerol, 0.1 mM EDTA, 250 mM imidazole and 5 mM betamercaptoethanol. Clean protein was pooled and desalted into a buffer containing 25 mM
Tris pH 8.0, 0.1 mM KCl, 15% glycerol, 0.1 mM EDTA and 2 mM DTT. Protein was flash
frozen and stored at -80oC.
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B.2 Biochemical and Inhibitory Evaluation of DHFR Enzymes
B.2a Michaelis-Mentin Kinetics
The Michaelis-Mentin constant (KM) and Vmax values for DHF and NADPH were
determined by Lineweaver- Burke plots generated by the monitoring the rate of NADPH
oxidation by DHFR via absorbance at 340 nm. The reaction was performed at room
temperature in buffer containing 20 mM TES pH 7.0, 50 mM KCl, 0.5 mM EDTA, 10 mM
beta-mercaptoethanol and 1 mg/mL BSA, and 2 µg/mL enzyme. For DHF, the enzymatic
activities were measured using 12.5-100 µM DHF with 20 µM NADPH and for NADPH,
the reactions were run with12.5-100 µM NADPH and a constant 50 µM DHF. KM and Vmax
values were determined by non-linear regression analysis using GraphPad. Kcat was
determined from Vmax using Equation 1.
Kcat=Vmax/[Et]

(1)

[Et]= total enzyme concentration

B.2b IC50 Value Determination
IC50 values were determined by enzyme inhibition assays via the monitoring the rate of
NADPH oxidation by DHFR via absorbance at 340 nm. The reaction was performed at
room temperature in buffer containing 20 mM TES pH 7.0, 50 mM KCl, 0.5 mM EDTA, 10
mM beta-mercaptoethanol and 1 mg/mL BSA, 0.1 mM NADPH and 2 µg/mL enzyme.
Inhibitor in DMSO was added to the enzyme/NADPH mixture and incubated for 5 minutes
prior to the addition of 0.1 mM DHF in 50 mM TES inhibitor volume and concentration is
based on conditions at which activity is reduced by 50%. Alternate IC50s (Chapter 2,
Table 1) were determined using the same procedure however the 5 minute protein:
NADPH: inhibitor incubation was removed. The IC50s were determined using Equations 2
-4.
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Enzyme Activity (µM/min)= (∆A340 *0.041)/ (∆t (sec)/60)

(2)

IC50 (µM)= (inh vol. (µL)/ % Inhibition)*50/550)*inh conc. (mM) *1000

(3)

% inhibition = 1-(Activityinh/ActvityEnz)*100

(4)

IC50s were converted to KI through use of Equation 5.
Ki= IC50/ (100/KM +1)

(5)

B.2c Dissociation Experiments
Steady-state NADPH turnover rate was determined by performing enzyme inhibition
assays following 18h of 4oC incubation with 2 µg/mL purified enzyme, 100 µM NADPH
and 50 µM inhibitor in buffer containing 20 mM TES, 50 mM KCl, 0.5 mM EDTA, 10 mM
beta-mercaptoethanol and 1 mg/mL BSA. The reaction was initiated with 0.1 mM DHF
and monitored at an absorbance of 340 nm. The steady-state NADPH rate was
extrapolated from data by converting the slope of A340 vs time to change in NADPH
concentration using a molar extinction coefficient of 6.2x103 Lmol-1cm-1.

B.3 Antibacterial Evaluation of Antifolates and Antibiotics
B.3a Minimum Inhibitory Concentration Determination
Minimum Inhibitory Concentrations (MICs) were determined according to the Clinical and
Laboratory Standards Institute Guideline’s Standard4 micro-dilution broth assay using a
final inoculum of 5 × 105 cfu/mL in Isosensitest Broth (Oxoid) using half-area 96-well
plates. The 96-well plate was set-up so that the highest inhibitor, 20µg/mL inhibitor in
Isosensitest broth, was loaded into the first column and then a series of 2-fold dilutions
were preformed. The final volume of compound in the 96-well plate is 50µL. The inoculum
prepared was by diluting the bacteria to an A600 =0.130 followed by a 1:100 dilution into
sterile isosensitest broth. 50µL of the diluted inoculum was added to each well and the
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plate was covered and placed in the incubator for 37oC for 18 hours. MICs were defined
as the lowest concentration to visually inhibit bacterial growth and are confirmed by use of
Alamar

Blue

(Life

Technologies).

UCP

compounds

(PLAs),

trimethoprim,

sulfamethoxazole, levofloxacin and linezolid are kept in DMSO, whereas erythromycin
was dissolved in ethanol and ciprofloxacin in 0.1N HCl.

B.3b Thymidine Rescue Minimum Inhibitory Concentration Determination
Minimum Inhibitory Concentrations (MICs) were determined according to the Clinical and
Laboratory Standards Institute Guideline’s Standard micro-dilution broth assay using a
final inoculum of 5 × 105 cfu/mL in Isosensitest Broth (Oxoid) using half-area 96-well
plates. The 96-well plate was set-up so that the highest inhibitor, 20 µg/mL inhibitor in
Isosensitest broth, was loaded into the first column and then a series of 2-fold dilutions
were preformed. The final volume of compound in the 96-well plate is 50µL. The inoculum
was prepared by diluting the bacteria to an A600 =0.130 followed by a 1:100 dilution into
sterile isosensitest broth containing 20µg/mL of thymidine (Sigma Aldrich, in water). 50µL
of the diluted inoculum was added to each well so that the final thymidine concentration is
10µg/mL and the plate was covered and placed in the incubator for 37oC for 18 hours.
MICs were defined as the lowest concentration to visually inhibit bacterial growth and are
confirmed by use of Alamar Blue (Life Technologies)

B.3c Sulfamethoxazole Synergy Minimum Inhibitory Concentration Determination
Minimum Inhibitory Concentrations (MICs) were determined according to the Clinical and
Laboratory Standards Institute Guideline’s Standard micro-dilution broth assay using a
final inoculum of 5 × 105 cfu/mL in Isosensitest Broth (Oxoid) using half-area 96-well
plates. The 96-well plate was set-up so that the highest inhibitor, 20 µg/mL inhibitor in
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Isosensitest broth, was loaded into the first column and then a series of 2-fold dilutions
were preformed. The final volume of compound in the 96-well plate is 50µL. The inoculum
was prepared by diluting the bacteria to an A600 =0.130 followed by a 1:100 dilution into
sterile isosensitest broth containing 200 µg/mL or 2 µg/mL of sulfamethoxazole (SMX) for
SMX resistant and susceptible strains, respectively (Sigma Aldrich, in DMSO). 50µL of
the diluted inoculum was added to each well so that the final thymidine concentration is
100 µg/mL or 1 µg/mL and the plate was covered and placed in the incubator for 37oC for
18 hours. MICs were defined as the lowest concentration to visually inhibit bacterial
growth and are confirmed by use of Alamar Blue (Life Technologies)

B.4 UCP1006 Resistance Mutant Generation and Characterization
B.4a Resistance Generation and Selection
Resistant strains were selected by plating 100 µL of overnight culture (approx. 1012
CFU/mL) of progenitor strain on Isosensitest (Oxoid) agar plates containing 6x MIC of
UCP1006 (MIC=0.0781) and incubated at 37 °C for 18 hours. Single colonies were
isolated and the dfrB gene was identified by directly sequencing the colony PCR product.

B.4b Direct Colony PCR
The colony was isolated via inoculating loop and lysed using a solution of 1 mg/mL
lysostaphin (Sigma Aldrich, in water) and 20 µg/mL proteinase K (Sigma Aldrich, in 0.1 M
Tris, pH 7.5). The gene was amplified using:
Forward primer (5’-ATGACTTTATCCATTCTAGTTGC-3’)
Reverse: primer (5’-TTATTTTTTACGAATTAAATGTAG-3’)
and rTaq Polymerase (Takara) using the following PCR procedure: 2 min denaturation at
95oC, 30 cycles of 95oC denaturation for 30 sec, 55oC annealing for 30 sec, 1 min 72oC
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extension followed by a final 10 minute extension at 72oC. PCR products were purified
using Promega Wizard SV Gel and PCR Clean Up system, following manufacturers
protocol, confirmed on a 1.2% w/v agarose gel visualized with ethidium bromide and
sequenced using the sense primer.

B.4c Mutational Frequency Determination
The mutational frequency of UCP1006 was determined by the number of resulting
colonies divided by the total inoculum (1x1011 CFU/mL) for each progenitor strain. The
frequency of the specific mutations was determined by multiplying the mutational
frequency for the inhibitor-strain pair by the frequency of sequenced colonies containing
the specific mutation.

B.4d Pair-wise Fitness Assay
Relative strain fitness was determined by pair-wise competition assays5 with trimethoprim
as the selective agent. Cell growth was monitored every 20 minutes via A600 and the
doubling time of the strains was determined by monitoring cell growth in the log phase at
an absorbance of 600 nm every 15 minutes for a total of 180 minutes. Fitness was
calculated using the following Equation 6.

( R(0))
ln ( S(24)
S(0))

ln R(24)
Fitness =
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(6)

B.4e Doubling-time Growth Curves
1 mL of overnight culture was used to inoculate 50 mL of LB media. Culture was grown at
37oC at 225 RPM and growth was monitored at A600 every 30 minutes. The doubling time
was determined from the linear portion of the growth curve using Equation 7.
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 =

∆!"#$∗!"#!
!"# !"#$% !"#$. !!"# (!"#$%& !"#$.)

(7)

B.5 Clinical Strain Characterization
B.5a Clonal Analysis
SpaA-typing was performed by Charles River using Accugenix’s AccuGENX-ST service
to identify clonality among isolates.

B.5b Genomic DNA Extraction and Next Generation Genomic Sequencing
Genomic DNA was isolated using Promega Wizard Genomic DNA Isolation kit. DNA
extracts were quantified using the Quant-iT PicoGreen kit (invitrogen, ThermoFisher
Scientific). One ng of genomic DNA was fragmented, adapter sequences attached, size
selected and cleaned using the Nextera XT Library Preparation kit (Illumina, Inc.)
according to the manufacturer’s protocol. Libraries were validated and mean insert length
was calculated using a Bioanalyzer High Sensitivity chip (Agilent Technologies). The
libraries were sequenced on the MiSeq using v2 2x250 base pair kit (Illumina, Inc). The
genome was assembled using CLC Workbench and annotated using the Rast Server6-8.
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B.5c PCR Identification and Sequencing
PCR on gel purified genomic and plasmid DNA was performed to detect the presence of
dfrB, dfrA, dfrG and dfrK genes.
Table 1 TMPS and TMPR DHFR PCR Primers9
Enzyme
DfrB- Forward
DfrB- Reverse
DfrA-Forward
DfrA-Reverse
DfrG-Forward
DfrG-Reverse
DfrK-Forward
DfrK-Reverse

Primer (5’-3’)
ATGACTTTATCCATTCTAGTTGC
TTATTTTTTACGAATTAAATGTAG
ACTGACCACTGGGAATACACT
CGACTTCCCAGTTTTCGAATGT
TTTCTTTGATTGCTGCGATG
CCCTTTTTGGGCAAATACCT
GAGAATCCCAGAGGATTGGG
CAAGAAGCTTTTCGCTCATAAA

Annealing Temp (oC)
55
52
55
55

PCR was performed using rTaq Polymerase (Takara), following standard PCR
procedures. PCR product was purified using Promega SV Gel and PCR Clean-Up
System, following manufacturers procedures. Purified PCR reactions were run on 1.2%
agarose gels and visualized with ethidium bromide using 2-Log Ladder as a size
comparator (Thermo Scientific). The sequences were confirmed via Sanger Sequencing
using the corresponding forward primer as the sequencing primer.

B.5d Clinical Antibiotic Susceptibility Determination
Susceptibilities were determined using Sensititre Gram Positive plates (Remel,
ThermoFisher Scientific) using Mueller-Hinton Broth and an inoculum of 1x105 CFU/mL.
The plates were incubated for 18 hours at 37oC and MICs were colorimetrically
determined

using

Alamar

Blue

(ThermoFisher

Scientific).

Susceptible/Intermediate/Resistant designations were made based on CLSI breakpoint
standards.
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B.6 Crystal Growth Conditions and Protein Crystallography
B.6a Wild-type DHFR Crystal Structures
DfrB: NADPH: UCP1061
Purified SaDHFR at 17 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1061
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated
on ice for 2 hours. Equal volumes of protein solution were added to an optimized buffer
solution containing 0.1M MES, pH 6.5, 0.1M sodium acetate, 13% PEG 10,000 and
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days.
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol.
Data were collected remotely on beamline X25A at Brookhaven National Laboratories.
Data were indexed and scaled using HKL2000. Phaser was used to identify molecular
replacement solutions using PDB ID: 3F0Q10 as a probe. Coot11 and Phenix12 were used
for structure refinement until acceptable RWork and RFree were achieved.

DfrB: NADPH: UCP1062
Purified SaDHFR at 21 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1062
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated
on ice for 2 hours. Equal volumes of protein solution were added to an optimized buffer
solution containing 0.1M MES, pH 6.0, 0.1M sodium acetate, 13% PEG 10,000 and
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days.
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol.
Data were collected at the Rigaku HighFlux HomeLab Protein Crystallography X-Ray
system at the University of Connecticut. Data was indexed and scaled using d*TREK.
Phaser was used to identify molecular replacement solutions for the structures of
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Sa(F98Y):NADPH using PDB: 3F0Q as a probe. The programs Coot and Phenix were
used for structure refinement until acceptable Rwork and Rfree were achieved.

DfrB: NADPH: UCP1070
Purified SaDHFR at 21 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1070
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated
on ice for 2 hours. Equal volumes of protein solution were added to an optimized buffer
solution containing 0.1M MES, pH 6.0, 0.3M sodium acetate, 13% PEG 10,000 and
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days.
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol.
Data were collected at the Rigaku HighFlux HomeLab Protein Crystallography X-Ray
system at the University of Connecticut. Data was indexed and scaled using d*TREK.
Phaser was used to identify molecular replacement solutions for the structures of
Sa(F98Y):NADPH using PDB: 3F0Q as a probe. The programs Coot and Phenix were
used for structure refinement until acceptable Rwork and Rfree were achieved.

DfrB: NADPH: UCP1106
Purified SaDHFR at 18 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1106
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated
on ice for 3 hours. Equal volumes of protein solution were added to an optimized buffer
solution containing 0.1M MES, pH 5.5, 0.2M sodium acetate, 17% PEG 10,000 and
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days.
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol.
Data were collected remotely on beamline 7-1 at Stanford Synchrotron Radiation
Lightsource, SLAC National Accelerator Laboratory. Data were indexed and scaled using
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HKL2000. Phaser was used to identify molecular replacement solutions using PDB ID:
3F0Q as a probe. Coot and Phenix were used for structure refinement until acceptable
RWork and RFree were achieved.

DfrB: NADPH: UCP1175
Purified SaDHFR at 18mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1175
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated
on ice for 3 hours. Equal volumes of protein solution were added to an optimized buffer
solution containing 0.1M MES, pH 5.5, 0.2M sodium acetate, 17% PEG 10,000 and
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days.
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol.
Data were collected remotely on beamline 7-1 at Stanford Synchrotron Radiation
Lightsource, SLAC National Accelerator Laboratory. Data were indexed and scaled using
HKL2000. Phaser was used to identify molecular replacement solutions using PDB ID:
3F0Q as a probe. Coot and Phenix were used for structure refinement until acceptable
RWork and RFree were achieved.

DfrB: NADPH: UCP1191
Purified SaDHFR at 13 mg/mL protein was co-crystallized with 2 mM NADPH and 1 mM
UCP1191 in DMSO via the hanging drop method. The mixture of protein and cofactor was
incubated on ice for 3 hours. Equal volumes of protein solution were added to an
optimized buffer solution containing 0.1 M MES, pH 5.0, 0.3 M sodium acetate, 17% PEG
10,000 and 12.5% gamma-butyrolactone. Crystals were harvested and frozen in cryoprotectant buffer containing 25% glycerol. Data were collected remotely on beamline 14-1
at Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory.
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Data were indexed and scaled using HKL2000. Phaser was used to identify molecular
replacement solutions using PDB ID: 3F0Q as a probe. Coot and Phenix were used for
structure refinement until acceptable RWork and RFree were achieved.

B.6b S. aureus F98Y Mutant DHFR Crystal Structures
DfrB (F98Y): NADPH Apo
Sa(F98Y)DHFR was co-crystallized with NADPH using the hanging drop vaporization
method. Purified protein (20 mg/mL) was incubated with 2 mM NADPH (Sigma-Aldrich)
and for 2h on ice. Equal volumes of the protein: cofactor solution were mixed with an
optimized crystallization solution containing 13 % PEG 10,000, 0.1 M sodium acetate,
0.1-0.2 M MES pH 6.0 and 5% gamma-butyrolactone. When stored at 4oC, conditions
typically yielded crystals within 7 days. Crystals were frozen in cyro-protectant buffer
containing 25 % glycerol. Data were collected at the Rigaku HighFlux HomeLab Protein
Crystallography X-Ray system at the University of Connecticut. Data was indexed and
scaled using d*TREK. Phaser was used to identify molecular replacement solutions for
the structures of Sa(F98Y):NADPH using PDB: 3FQO as a probe. The programs Coot
and Phenix were used for structure refinement until acceptable Rwork and Rfree were
achieved.

DfrB (F98Y): NADPH: UCP1106
DfrB (F98Y) DHFR was co- crystallized with NADPH and UCP1106 using the hanging
drop vaporization method. Potein at 14.25 mg/mL was incubated with 1 mM UCP1106
and 2 mM NADPH (Sigma Aldrich) for three hours. It was crystallized in a solution
containing 0.1 M MES pH 6.0, 0.2 M Sodium acetate, 13% PEG 10,000 and 20% gammabutyrolactone. Crystals were frozen with well solution containing 25% glycerol. Data were
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collected remotely at Stanford Synchrotron Radiation Lightsource on beamline 7-1. Data
was indexed and scaled using HKL2000.

Phaser was used to identify molecular

replacement solutions for the structures of Sa(F98Y):NADPH:UCP1106 using PDB: 3F0Q
as a probe. The programs Coot and Phenix were used for structure refinement until
acceptable Rwork and Rfree were achieved.

B.6c S. aureus H30N Mutant DHFR Crystal Structures
DfrB (H30N): NADPH: UCP1106
DfrB(H30N) DHFR at 14.25 mg/mL was incubated with 1 mM UCP1106 and 2 mM
NADPH for three hours. It was crystallized using the hanging drop method in solution
containing 0.1 M MES pH 5.75, 0.3M Sodium acetate, 17% PEG 10,000 and 20%
gamma-butyrolactone. Crystals were frozen with well solution containing 25% glycerol..
Data were collected remotely at Stanford Synchrotron Radiation Lightsource on beamline
7-1. Data was indexed and scaled using HKL2000.

Phaser was used to identify

molecular replacement solutions for the structures of Sa(H30N):NADPH:UCP1106 using
PDB: 3F0Q as a probe.

The programs Coot and Phenix were used for structure

refinement until acceptable Rwork and Rfree were achieved.

B.6d S. aureus H30N, F98Y Mutant DHFR Crystal Structures
DfrB (H30N, F98Y): NADPH: UCP1106
Sa(F98Y/H30N) DHFR at 21 mg/mL was incubated with 1 mM UCP1106 and 2 mM
NADPH for three hours. It was crystallized using the hanging drop vaporization method in
a solution containing 0.1 M MES, pH 6.0, 0.2 M Sodium acetate and 13% PEG 10,000
and 20% gamma-butyrolactone. Crystals were frozen using well solution containing 25%
glycerol. Data were collected remotely at Stanford Synchrotron Radiation Lightsource on
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beamline 7-1 and indexed and scaled using HKL2000.

Phaser was used to identify

molecular replacement solutions for the structures of Sa(H30N, F98Y):NADPH:UCP1106
using PDB: 3F0Q as a probe. The programs Coot and Phenix were used for structure
refinement until acceptable Rwork and Rfree were achieved.

B.6e S. aureus V31L, F98Y Mutant DHFR Crystal Structures
DfrB (V31L, F98Y):NADPH: UCP1021
Sa(V31L, F98Y)DHFR was co-crystallized with NADPH and UCP1021 using the hanging
drop vaporization method. Purified protein (20 mg/mL) was incubated with 2 mM NADPH
(Sigma-Aldrich) and 1 mM inhibitor in DMSO for 2h on ice. Equal volumes of the protein:
cofactor: inhibitor solution were mixed with an optimized crystallization solution containing
13 % PEG 10,000, 0.1 M sodium acetate, 0.1-0.2 M MES pH 6.0 and 5% gammabutyrolactone Crystals were frozen in cyro-protectant buffer containing 25 % glycerol.
High-resolution data were collected on the X4A Beamline at Brookhaven National
Laboratories. Data for Sa(V31L, F98Y)DHFR:NADPH were indexed and scaled using
HKL2000. Phaserwas used to identify molecular replacement solutions for the structures
of Sa(V31L, F98Y)DHFR:NADPH and Sa(F98Y):NADPH using PDB: 3F0U The programs
Coot and Phenix were used for structure refinement until acceptable Rwork and Rfree were
achieved.
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Appendix C Crystallographic Data Collection and Refinement Statistics
C.1 Structures Presented in Chapter 2
Table C1 Data Collection and Refinement Statistics for Pyridine PLAs
Sa(WT):NADPH:
Sa(WT):NADPH:
Sa(WT):NADPH:
UCP1061
UCP1062
UCP1070
PDB ID
4XEC
4TU5
N/A
Space group
P6122
P6122
P6122
No. monomers in
1
1
1
asymmetric unit
Unit cell (a, b, c in Å)
78.90, 78.90,
79.14, 79.14,
79.048, 079.048,
108.12
108.99
109.04
Resolution (Å)
31.89-2.69
58.02-2.16
50-1.66
Completeness % (last
99.97 (98.6)
99.8 (100)
99.08
shell, %)
Unique reflections
5,929
11,493
34, 438
Redundancy (last
18.2 (17.4)
12.94 (13.26)
14.3 (14.1)
shell)
Rsym, (last shell)
0.160 (0.428)
0.154 (0.437)
0.109(0.699)
<I/σ> (last shell)
38.6 (9.0)
8.8 (3.6)
35.1 (4.5)
R-factor/Rfree
0.1564, 0.2327
0.1990 , 0.2495
0.2241, 0.2384
No. of atoms (protein,
1,398
1,496
1,517
ligands, solvent)
Rms deviation bond
0.008, 1.343
0.008, 1.248
0.011, 1.980
lengths (Å), angles
(deg)
Average B factor for
30.22
30.75
24.17
protein (Å2)
Average B factor for
26.89 (NADPH)
25.64 (NADPH)
16.92 (NADPH)
2
ligand (Å )
33.49 (DRG)
35.86 (DRG)
23.89 (DRG)
Average B factor for
28.17
39.06
27.13
solvent molecules (Å2)
Residues in most
96.79
97.44
98.75
favored regions (%)a
Residues in additional
3.21
2.56
1.25
allowed regions (%)a
Residues in
0
0
0
disallowed regions
(%)a
Collection Location
Brookhaven
Rigaku HighFlux
National Lab
HomeLab
NSLS X25
Beamline
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Table C2 Data Collection and Refinement Statistics for Carboxylate PLAs

PDB ID
Space group
No. monomers in
asymmetric unit
Unit cell (a, b, c in Å)

Resolution (Å)
Completeness % (last
shell, %)
Unique reflections
Redundancy (last
shell)
Rsym, (last shell)
<I/σ> (last shell)
R-factor/Rfree
No. of atoms (protein,
ligands, solvent)
Rms deviation bond
lengths (Å), angles
(deg)
Average B factor for
protein (Å2)
Average B factor for
ligand (Å2)
Average B factor for
solvent molecules (Å2)
Residues in most
favored regions (%)a
Residues in additional
allowed regions (%)a
Residues in disallowed
regions (%)a
Collection Location

Sa(WT):NADPH:
UCP1006
5HF0

Sa(WT):NADPH:
UCP1175
5HF2

Sa(WT):NADPH:
UCP1191
5JG0

P6122

P6122

P6122

1

1

1

79.09, 79.09,
107.93
90.0, 90.0, 120.0

79.02, 79.02,
108.25
90.0, 90.0, 120.0

78.86, 78.86, 106.43
90.0, 90.0, 120.0

32.65-2.24 (2.282.24)

25.15-1.81 (1.871.81)

39.44-1.88 (1.911.88)

100 (99.9)

99.8 (100)

99.75 (97.0)

10,059

18,798

16, 498

14 (14.2)

12.32 (12.03)

16.7 (17.4)

0.055 (0.144)
68.5 (31.9)

0.110 (0.644)
11.7 (2.3)

0.107 (0.483)
41.2 (5.52)

0.1703/ 0.2167

0.1991/0.2322

0.1765/ 0.2172

1,499

1,489

1,458

0.008, 1.912

0.009. 1.810

0.007, 1.238

22.34

28.01

29.54

17.46 α-NADPH
16.91 β-NADPH
31.29 Inhibitor

24.65 α-NADPH
24.93 Inhibitor

25.34 β-NADPH
34.66 Inhibitor

25.25

35.10

35.74

96.86

98.73

98.12

3.14

1.27

1.88

0

0

0

SSRL Beamline 71

Rigaku HighFlux007

SSRL Beamline 7-1
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C.2 Structures Presented in Chapter 3
Table C3 Data Collection and Refinement Statistics for K* Predicted Mutants
Sa(V31L,F98Y) Apo
Sa (F98Y) Apo
PDB ID
Space group
P6122
P6122
No. monomers in
1
1
asymmetric unit
Unit cell (a, b, c in Å)
79.335, 79.335,
79.26, 79.26, 107.42
107.553
Resolution (Å)
68.706- 1.559
42.30-2.04 (2.51-2.04)
Completeness %
99.8 (98.6)
98.7 (98.5)
(last shell, %)
Unique reflections
29,153
13,132
Redundancy (last
13.7 (13.5)
10.22 (10.44)
shell)
Rsym, (last shell)
0.070 (0.340)
<I/σ> (last shell)
31.7 (20.0)
16.9 (5.6)
R-factor/Rfree
0.1993/ 0.2221
0.1752/ 0.2330
No. of atoms
1,524
1,446
(protein, ligands,
solvent)
Rms deviation bond
0.007, 1.275
0.007, 1.205
lengths (Å), angles
(deg)
Average B factor for
20.68
28.75
protein (Å2)
Average B factor for
13.14 (NADPH)
21.11 (NADPH)
ligand (Å2)
Average B factor for
32.08
35.18
solvent molecules
(Å2)
Residues in most
98.15
98.10
favored regions (%)a
Residues in
1.85
1.90
additional allowed
regions (%)a
Residues in
0
0
disallowed regions
(%)a
Collection Location
BNL X4A
Rigaku MicroMax
HomeFlux
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C.3 Structures Presented in Chapter 4
Table C4 Data Collection and Refinement Statistics for Mutant DHFR with UCP1106
Sa(H30N, F98Y):
Sa(F98Y):NADPH: Sa(H30N):NADPH:
NADPH:
UCP1106
UCP1106
UCP1106
PDB ID
5ISP
5IST
5ISQ
Space group
P6122
P6122
P6122
No. monomers in
1
1
1
asymmetric unit
79.13, 79.13,
79.07, 79.07,
78.99, 78.99,
Unit cell (a, b, c in Å)
107.41
108.42
108.69
Resolution (Å)
28.85-1.84
31.96-1.72
28.95-1.90
Completeness % (last
99.9 (100)
99.05
99.95
shell, %)
Unique reflections
17,979
21,572
16,379
Redundancy (last
8.2 (8.3)
9.3 (9.1)
9.1 (9.1)
shell)
Rsym, (last shell)
0.105 (0.516)
0.108 (0.590)
0.095 (0.400)
<I/σ> (last shell)
48.4 (5.16)
36.0 (4.36)
44.6 (7.82)
R-factor/Rfree
0.1803/ 0.2096
0.1872/ 0.2305
0.1798/ 0.2219
No. of atoms (protein,
1508
1576
1478
ligands, solvent)
Rms deviation bond
lengths (Å), angles
0.08, 1.251
0.07, 1.872
0.008, 1.239
(deg)
Average B factor for
29.39
20.62
25.64
protein (Å2)
14.89 tNADPH
Average B factor for
21.64 NADPH
18.97 NADPH
14.38
β-NADPH
ligand (Å2)
39.87 Inhibitor
31.28 Inhibitor
26.46 Inhibitor
Average B factor for
36.36
29.22
31.72
solvent molecules (Å2)
Residues in most
97.56
98.15
98.10
favored regions (%)a
Residues in additional
2.44
1.85
1.90
allowed regions (%)a
Residues in
disallowed regions
0
0
0
(%)a
Collection Location
SSRL 7-1
SSRL 7-1
SSRL 7-1
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